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Key messages
Policy Facts
It is a fundamental duty of Government to implement policies that 
improve social welfare. Policies that affect risks to human life and 
health are often cross-cutting in Departmental reach and are 
examples of how welfare can be improved.
Risks to life and health range from risks of immediate harm (e.g. 
traffic or work-related accidents) to lifetime risks (e.g. air pollution 
impacts, latent cancers) and uncertain, future risks (e.g. climate 
change; global trade-related food safety).
It is also the Government’s duty to deliver ‘value for money’. This 
requires valuation of these different types of risk reductions. HM 
Treasury ‘Green Book’ guidance sets out different approaches to 
valuing life and health impacts:
	 Value of a Prevented Fatality (VPF): values small changes in 
fatality risks;
	 Value of Statistical Life Year (value of a SLY or VOLY): values the 
impact of risks to the length of life;
	 Quality Adjusted Life Year (QALY): values changes in health-
related quality of life and length of life.
Findings
Currently, recommended Green Book values for the VPF and the 
monetary value of a QALY are based on a very small sample-survey 
of the UK public carried out in the 1990s. The only UK study to 
directly elicit a VOLY is also outdated, but was carried out on larger 
sample. Updated values for changes in longevity derived from a 
broadly representative sample of the UK population would better 
reflect current preferences.
Due to the limited number of UK VOLY studies, a VOLY cannot be 
generated from secondary data. Appropriate revealed preference/
behavioural data does not exist in the UK to estimate a VOLY. As 
such, a stated preference survey drawing on the most up to date 
methodological practices is the only viable option.
This report finds that a VOLY can be derived that has a clear 
conceptual link to the monetary value of a QALY and VPF. It also 
finds that the three measures can be empirically derived from a 
common source, reflecting the same underlying preferences over 
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health and safety. This maximises consistency across policy 
Appraisals but allows flexibility and choice over the valuation 
measure Government Departments use. Whilst other valuation 
methods are available to elicit these values separately or indirectly 
exist, this report finds that the proposed framework delivers the 
most clarity in this respect. Empirically, the proposed method has 
benefitted from recent developments and improvements
Conclusions
Longevity valuation is evolving and future research will improve our 
understanding of this complex issue. However, the technology exists 
now to generate a theoretically robust, evidence-based and updated 
valuation of risk to human life and health.
Applying such values would lead to better and more informed policy 
decisions and would have major implications not only for efficiency 
of government spending but also for equity in population wellbeing.
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Executive summary
Context
Risks to life, longevity and health can be monetised for policy 
analysis. The Project Group Consortium brought together by the 
HSE has a particular concern with the robustness of the monetary 
value placed on reducing risks to longevity: the value of a life year.
The focus of this report is to assess the need for and feasibility of 
undertaking new large-scale primary research to update the Value 
of a Life Year (VOLY) and Willingness-To-Pay for a Quality Adjusted 
Life-Year (WTP-QALY), used by the UK government Departments 
and Agencies.
In particular, it addresses the question of whether a VOLY that is 
compatible with a Value of a Prevented Fatality (VPF) and WTP-
QALY could be elicited directly on the basis of current theoretical 
and empirical practice.
Method
The methodology for this scoping study comprises three distinct 
phases
	 Literature Reviews: a set of literature reviews addressing five 
broader and overarching research questions (RQs I, II, III, IV and 
V) which were set out in the Tender and are presented in the 
Annexes to this report and referred to below.
	 Synthesis: based on the literature reviews and in-depth team 
discussions agreement and conclusions were drawn on;
	 The need for and feasibility of undertaking new primary 
research and the most appropriate methodology
	 Derivation and development of the underlying conceptual 
framework
	 Strengths and limitations of the associated empirical methods
	 Additional issues with respect to policy application in practice 
that are both cross-cutting and not restricted to any particular 
valuation methodology
	 Report: content derived from a combination of phases I and II.
Each Section of the report addresses specific questions and/or 
issues arising from phases I and II above
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Can a reliable VOLY be derived from existing 
studies? (Section 2)
A review of the relevant literature (RQI) noted the significant variation 
in VOLY values and heterogeneity of methods precluded the 
identification of a VOLY value robust and reliable enough for future 
policymaking. Significant differences in timing, value elicitation and 
risk communication methods, amongst other things, meant that a 
robust value could not be identified. Three studies did generate a 
value close to current value £60,000 for the monetary value of a 
QALY or VOLY but some fundamental concerns were raised with 
respect to their reliability for policy purposes. Similarly, it was noted 
that whilst there were a few primary studies converging around a 
value of £30,000-£40,000, these were too few in number and varied 
too much in terms of timing and/or methodology to provide a 
reliable corpus of studies as a whole. In the UK, we found only three 
primary VOLY studies and three primary UK WTP-QALY studies.
Studies were also compared using a qualitative-based assessment 
framework to establish whether a particular study or studies could 
be considered to generate a reliable, gold-standard value from a 
methodological point of view. The primary purpose of this approach 
was to allow each study to be assessed in a consistent manner 
across a range of relevant factors, as opposed to generating an 
(implied) ranking of one study over another. At the most general 
level, it was noted that this assessment identified a wide variety of 
practices with respect to overall design and that it was not really 
possible to assess how these differences might affect convergence 
or divergence of any resulting VOLY.
RQI also reviewed the WTP-QALY literature using similar procedures 
with a view to establishing the degree of consistency amongst 
estimates and procedures and/or establishing whether a VOLY 
could be derived from this literature instead. For reasons similar to 
those outlined already, it was concluded that a VOLY robust enough 
for future policymaking could not be derived from this literature.
Thus, no reliable UK VOLY or WTP-QALY can be derived from 
existing stated preference (or revealed preference) studies (RQI), 
either from a reference ‘gold standard’ study nor a meta-analysis of 
existing UK VOLY and WTP-QALY studies.
Given recent methodological advances in mortality risk valuation 
practice, we recommend that new primary research is required to 
update the current values, which, as noted, are based on two dated 
studies
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Can a new primary VOLY be elicited? (Sections 2, 3)
The report develops and sets out a unifying framework that demonstrates 
a conceptual link between the VPF, VOLY and WTP-QALY, bringing 
together the two traditions underpinning the calculation of these values.
This framework is developed in the context of a one-period model. 
In principle, it could be adapted to accommodate multi-period risk 
reductions (RQII; RQV).
Alternative methods to the one proposed do exist (RQII). For 
example, a VOLY can be indirectly estimated from a VPF (Mason et 
al., 2008) as could a WTP-QALY although this would require further 
adjustment. Other methods are not demonstrably superior to the 
method proposed in this report; and some would require more 
significant methodological development.
We recommend a ‘chained approach’ as the preferred method to 
deploy in a survey to directly elicit a VOLY. This involves:
	 a two-stage process to generate the value of a life expectancy 
gain which establishes how mortality risk reductions and/or 
improvements in health (policy deliverable) are converted into 
gains in life expectancy (policy outcome);
	 the estimation of a value function that encompasses life 
expectancy gains from a few hours to a few months, reflecting a 
broad class of policy outcomes;
	 an empirical application based on WTP, Standard Gamble (SG) 
and Time-Trade-Off (TTO) data, analysed in combination.
It has a number of advantages over other methods:
	 the chained approach breaks the valuation process down into 
two steps that are conceptually and cognitively more manageable 
than direct valuation;
	 elicited values map directly and transparently to the conceptual 
framework;
	 VOLY, VPF and WTP-QALY values are derived from the same 
data set i.e. from the same underlying preferences, so any 
observed differences in values cannot be driven by differences in 
methods; comparisons of values derived from different methods 
are less reliable and require additional, often heroic, assumptions;
	 a VOLY and WTP-QALY can be estimated based on existing 
approaches and both traditions can be harnessed to validate/
triangulate any change in recommended policy values. These 
methods reflect currently available technologies and have been 
implemented successfully in the field in the context of a VPF and 
WTP-QALY;
	 using the same methodology, the VPF currently recommended 
for regulatory analysis can be updated to account for current 
preferences.
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Nevertheless, the validity of any empirical estimates should not be 
assumed. In the literature, concerns have been raised that the chaining 
process amplifies the effect of people’s imprecise preferences on 
valuations, thereby increasing the number of outliers. It is possible that 
the same result would be observed in any new chaining study. However, 
methodological advances since 2011 have reduced the number of outlier 
observations excluded from WTP-QALY data to less than 10%. Similarly, 
with respect to the VPF and VOLY, more sophisticated information sets 
have been shown to reduce the insensitivities in valuation.
Efforts should therefore focus on (i) ensuring respondents 
understand the trade-offs when valuing life expectancy gains to 
minimise the number of extreme outliers and their impact on the 
final estimates; (ii) investigating the impact of combining the 
component parts of the method into either single or multiple chains.
Acquiring more information on how people derive their values and 
what they understand by life expectancy gains should be a priority, 
pursued in parallel with a new primary study. In a similar manner, 
qualitative information could also generate insights into peoples’ 
views on how the quantitative evidence is used in policy.
Age and Context (Sections 3, 4)
A VOLY is expected to vary with age (RQIV) and time preferences 
(see below), thus any new primary research should be stratified with 
respect to age (as well as income and geographical location) to test 
this empirically. Age-specific values could inform VOLY updates in 
the future as the population ages.
If a constant age-independent VOLY and constant age-independent 
VPF are used in policy this will lead to an inconsistency in how 
safety is valued across different projects. This inconsistency is not 
related to the robustness or otherwise of the values. As with the 
VPF, the VOLY is based on individual values for small reductions in 
the risk of death which are then aggregated to form the value used 
in policy. The process of aggregation differs across the two 
measures, but the underlying principle is the same.
The possibility of a ‘context free’ measure was considered (RQIV). 
The definition of ‘context’ is multi-faceted and can include almost 
anything. The evidence in the literature is such that it would be 
difficult to identify specific contextual features that can be expected 
to systematically affect a VOLY.
We use the term ‘generic’ VOLY instead, meaning a value that is not 
specific to a particular scenario description/risk reduction. By 
definition, the domain (e.g. road; air pollution; food) would be left 
unstated; however, if difficulties arise with respect to realism/
acceptability, a domain may have to be introduced into the survey.
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Discounting (Section 4)
This report is not prescriptive about how to deal with discounting in 
a new primary study, although a number of potential approaches are 
set out.
Current practice in the public sector is to use social time 
preferences to discount mortality/morbidity values. If individual 
discount rates could be recovered, either directly or indirectly, then 
this would allow WTP values to be re-inflated using personal 
discount rates. An aggregate VOLY increasing in value over time 
could then be recalculated using undiscounted values (to be 
subsequently discounted using the Social Rate of Time Preference 
(SRTP)). This would avoid the problem of ‘double discounting’.
Conclusions
A conceptual framework has been set out and empirical methods 
identified that could underpin a new primary study, one that would:
	 incorporate recent theoretical and empirical advances to improve 
the policy robustness of the three values, leading to better 
informed and consistent policy decisions in an area of fundamental 
importance to everyone i.e. longevity, safety and health.
	 generate a VOLY with a clear conceptual link to WTP-QALY and a 
VPF and facilitate the estimation of these measures from the 
same data set.
	 methods exist to operationalise the framework presented but 
should be subject to some further investigations and 
improvements. An in-depth and intensive approach to piloting is 
advocated given concerns that some aspects of the method may 
amplify the effect of people’s imprecise preferences on 
valuations, thereby increasing the number of outliers.
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1 Introduction
 1.1 Policy Background
It is the duty of a number of Government Departments to develop 
policies and interventions that improve the safety and/or health of 
the UK population. These include reducing the risk of death 
(mortality risks), increasing life expectancy and improving health-
related quality of life. Allocation of resources across these different 
options, and across the broader policy remit, must be done as 
efficiently and fairly as possible.
To facilitate this, these benefits can be monetarised in three 
alternative ways (HM Treasury, 2018):
	 Value of a Prevented Fatality (VPF): values small changes in 
fatality risks (mortality);
	 Value of Statistical Life Year (value of a SLY): values the impact of 
risks to the length of life;
	 Quality Adjusted Life Year (QALY): values changes in health-
related quality of life (morbidity) and length of life1.
Current guidance (HM Treasury, 2018; Annexe A2) recommends the 
following monetary values for the different measures:
	 VPF: £1m (1997 prices) updated to £ 1.6m (2010 prices)
	 VOLY: £60,000.
	 QALY: £60,000.
This approach allows flexibility with respect to the valuation measure 
that Government Departments use, although, as noted by Wolff and 
Orr (2009 p. 53) ‘There are good reasons not to replace VPFs with 
QALYs in safety contexts and good reasons not to replace QALYs 
with VPFs in health contexts’. However, for interventions delivering 
both longevity and changes in quality of life, the choice of which 
measure – if any – is far from clear. The inclusion of both is potentially 
important for efficient valuation and would make it easier to compare 
such policies with those that affect mortality risks.
What is required for policy purposes is a framework in which the 
value of a SLY has a clear conceptual link to the value of a QALY 
and the VPF. Hereafter, we refer to these three measures as value of 
a life year (VOLY), willingness-to-pay for a QALY (WTP-QALY)2 and 
1 When applied in other evaluation contexts (mainly in health), QALYs are not monetised.
2 To distinguish it from non-monetised measures of a QALY.
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VPF. Together, these values would provide quantitative information 
on how people value changes in life expectancy (delivered through 
risk reduction in the coming year and/or over the lifetime), in perfect 
or full health and in poorer health. In addition, clarifying the 
conceptual link between the three values would facilitate 
consistency in the use of a VOLY across different Government 
Departments and Agencies.
Schedule A3 notes that both the current VPF and VOLY estimates 
primarily used by UK Government Departments and Agencies are 
derived from the Carthy et al. (1999) study, although only the former 
are estimated directly from the individual-based data. The current 
approach to estimating a VOLY is described in Franklin (2015). Thus, 
whilst the conceptual link between the two measures is there, it is 
not as clear as it might be. In addition, the Carthy et al. (1999) study 
was carried out over 20 years ago and applying it to current 
interventions implicitly assumes that the tastes and preferences of 
the population with respect to safety have not changed markedly 
over time. Whether this assumption holds is an open question, as is 
their relationship – if any – to WTP-QALY.
 1.2 Aims
In line with the research brief, the overarching aims of this report are to:
	 assess the need for and feasibility of undertaking new large-
scale primary research to update the VOLY, and value of a QALY, 
used in the UK Government Departments and Agencies
	 describe the required scale and recommend appropriate 
methodology required for such a valuation study
	 review whether and how primary research could address some 
key aspects of the application of these valuations in practice
 1.3 Content
These overarching aims are addressed via two mechanisms
1. Literature reviews with respect to five research questions 
(Annexes):
	 RQI What are the relevant published estimates of the Value of a 
Life Year, and what are their strengths and weaknesses?
	 RQII What are the main methodological issues in deriving a Value 
of a Life Year and what approaches exist in literature for 
addressing these?
3 Statement Of Service Requirements For The Provision Of A Scoping Study On The Valuation Of Risks To 
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	 RQIII Can a Value of a Life Year be derived which is compatible 
with a Quality-Adjusted Life Year framework?
	 RQIV Is it possible to derive a context-free Value of a Life Year for 
application across different policy contexts?
	 RQV What is the relationship between the Value of a Life Year 
and the Value of a Prevented Fatality?
2. A ‘synthesis’ exercise drawing together the findings from a sub-
set of this literature.
	 The purpose of (ii) is to establish whether one conceptual and 
empirical framework for the elicitation of a VOLY can be derived, 
based on robust, available technologies. Further, ideally, this 
framework would be able to accommodate the VPF, VOLY and 
the monetary value of a QALY to provide Government 
Departments and Agencies with the flexibility to value the type of 
life expectancy or health outcomes delivered by their own 
policies using values derived from the same data set i.e. 
reflecting the same underlying set of preferences.
The report is based around three main sections: the derivation of a 
conceptual model that clarifies the relationship between the three 
measures, a (potential) empirical study to elicit a VOLY (and by 
extension, a VPF and a monetary value for a QALY) and an 
identification of some key cross cutting policy issues arising from 
the literature reviews and their synthesis. These are followed by a 
set of recommendations addressing the key issue i.e. the need for 
and feasibility of new primary research to elicit a VOLY.
A scoping study on the valuation of risks to life and health Page 15 of 75
Health and Safety Executive
2 A conceptual framework for the 
VPF, VOLY and WTP-QALY
This section assesses the need for and feasibility of undertaking 
new large-scale primary research to generate monetary estimates of 
both a VOLY and a WTP-QALY, as well as an updated VPF. It 
demonstrates that these values can be underpinned by the same 
conceptual framework and empirical data to facilitate consistency in 
UK Government regulatory analysis4.
 2.1 Existing literature and other approaches
The first stage is to establish the need for new primary research or 
whether a reliable ‘reference value’ can be sourced from the existing 
mortality risk valuation literature.
 2.1.1 Can a reliable ‘reference value’ for a VOLY be identified from 
the existing literature?
The findings of RQI directly address the need for new primary 
research. RQI reviewed the existing VOLY and WTP-QALY literature 
to establish whether a reliable ‘reference value’ for a VOLY could be 
identified either from existing studies as a whole or from a study or 
subset of studies that might be judged to reflect best practice 
across a range of factors.
The review concluded that the significant variation in values (e.g. 
£216-£230,113 for a VOLY; £970-£912,835 for WTP-QALY) and 
heterogeneity of methods precluded the identification of a VOLY 
based on an empirical consensus, although two distinct clusters of 
values were identified. Three studies (Mason et al., 2009; Grisolia et 
al., 2018 and Ryen and Svenson, 2015) were observed to generate a 
value close to £60,000 which is broadly in line with the estimation 
provided in Franklin (2015), but some fundamental concerns were 
raised with respect to their reliability for policy purposes. Whilst an 
additional study by Dolan et al. (2008) generated a VOLY in the range 
of £57,000, a direct comparison is inappropriate given the very 
different conceptual underpinning of the study (Subjective Wellbeing 
Analysis5). Similarly, it was found that whilst there were a few primary 
4 The purpose of this framework is not to identify categories of practical application for which the VOLY (as 
distinct from the VPF or WTP-QALY) is to be preferred.
5 This would require the (future) development of a preference-based framework establishing how a VOLY 
elicited under the assumptions of expected utility theory maps to that elicited under the assumptions of 
SWB, which is beyond the scope of this report.
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studies clustering around a value of £30,000-£40,000, once again, 
these were too few in number and varied too much in terms of timing 
and/or methodology to provide a reliable basis for a value.
Studies were also compared qualitatively with each other to 
establish whether a particular study or studies could be considered 
to generate a reliable value from a methodological point of view. 
Under this scenario, such a value need not map to either a 
reference value or values from other studies. An assessment 
framework was devised in RQI. Its primary purpose was to allow 
each study to be assessed in a consistent manner across a range of 
relevant factors, as opposed to generating an (implied) ranking of 
one study over another, although any study judged to perform well 
across all (or many) of the factors would clearly be preferred to a 
study performing poorly across these same factors.6
Thus, studies were compared across timing and location, elicitation 
procedures and standard economic consistency tests and data 
handling procedures (e.g. responsiveness of WTP to income; scope 
sensitivity; data cleaning). At the most general level, this assessment 
identified a wide variety of practices with respect to overall design 
and it was not realistic to assess how these differences might affect 
convergence or divergence of any resulting VOLY, either with 
respect to VOLYs from other studies and/or any ‘reference value’.
RQI also reviewed the WTP-QALY literature7 using similar 
procedures with a view to establishing the degree of consistency 
amongst estimates and procedures and/or establishing whether a 
‘reference’ VOLY could be derived from this literature instead. For 
reasons similar to those outlined already, it was concluded that this 
was not possible.
As the significant variation in values as a whole and the 
heterogeneity of methods precluded the identification of a specific 
VOLY, the second stage is to consider the feasibility of new primary 
research i.e. whether an empirical method exists in the literature that 
could be used – with or without adaptation – as opposed to 
developing a completely new method.
 2.1.2 Alternative methods to elicit a monetary value of a VOLY
RQV highlighted that a number of methods exist to elicit monetary 
values for fatality risk reductions in a survey, all of which should 
generate an equivalent value of a life year, providing they each were 
understood perfectly by respondents in a survey. However, the 
6 An additional assumption is that more recent, UK-based studies would be more likely to represent current 
preferences than other studies, particularly if they also employed methodological advances in elicitation 
procedures developed since the early studies in the 1990s.
7 Restricted to 21 papers reporting WTP-QALY estimates calculated from primary research studies.
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review in RQI suggests caution in this respect. More details can be 
found in RQV with respect to these methods, but the identified 
problems and/or uncertainties - which are summarised below – and/
or lack of compatibility with a WTP-QALY led the research team to 
reject them as methods to take forward in new primary research.
The first alternative would simply be to ask a representative sample 
of the population quite directly about their WTP for a marginal gain 
in life-expectancy e.g. Chilton et al. (2004). As well as losing a 
conceptual link to WTP-QALY (see Section 2.2 below), the first 
difficulty with this approach is that members of the public - most of 
whom will almost certainly be unfamiliar with the way in which life-
expectancy is defined and measured - are likely to regard a gain in 
remaining life-expectancy as constituting a simple ‘add-on’ to 
survival time at the end of life in poor health. The second problem is 
that the gains in life-expectancy to be valued will almost certainly 
need to be marginal gains in life-expectancy. For example, for an 
individual with 40 years of remaining life-expectancy, a halving of 
the current average risk of death as a car driver or passenger during 
the coming year would generate a gain in remaining life-expectancy 
of less than four hours, while an ongoing halving of the risk over 
future years would generate a gain of about three days. It would not 
be surprising if the individual stated that she would be willing to pay 
only a very limited amount, if anything at all, for the gain, particularly 
if the individual regarded it as an ‘add-on’ to survival time at the end 
of life.
A second, direct approach might be to extend the method 
developed in Nielsen et al. (2010) – in which respondents were 
asked to choose between gains in life expectancy generated by 
different types of perturbation in the vector of future hazard rates. If 
deployed in new primary research, respondents would also be 
asked to state their WTP for these different distributions, a so far 
empirically unverified approach. However, two potential problems 
arise. The first is that, in the two applications in the field (Nielsen et 
al., 2010; Hammitt and Tunҫel, 2015), it was found that preferences 
were more or less evenly distributed across the sample of 
respondents. This finding might be considered to be at odds with 
the theoretical analysis outlined in Jones-Lee et al. (2015) and RQV, 
suggesting at the very least, that further significant empirical 
investigation of the psychological underpinnings of people’s 
attitudes to the timing of hazard rate reductions would be required 
before this method could be recommended for use in large scale 
primary research. The second issue is that, so far, this method has 
been used for a relative valuation of different perturbations in the 
hazard rates that each generated the same gain in life expectancy. 
Further developing this method to allow for a monetary valuation 
would almost certainly require a protracted period of time to 
develop and test appropriately.
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Thirdly, a VOLY could be estimated, by a direct elicitation of WTP to 
reduce current risk and estimating the gain in life expectancy that 
such a risk reduction would generate for the individual (see for 
example Alberini et al., 2006). Two issues arise from using this 
approach.
The first is a well-established issue in attempts to directly elicit WTP 
for changes in fatality risks: insensitivity to scope. In the UK, Beattie 
et al., (1998) reported significant scope insensitivity issues on the 
individual level with up to 42% of respondents giving identical non-
zero CV responses for two different risk reduction. Similar concerns 
regarding non-fatal road injuries are reported in Jones-Lee et al. 
(1995) and Dubourg et al. (1997). These findings led directly to the 
development of the ‘chained’ approach to estimating a VPF in the 
UK (Carthy et al., 1999). Hammitt et al. (2019) used the direct 
elicitation approach in China in 2016. Their consistency test had two 
components 1) positivity (elicited WTP must be strictly positive) and 
2) proportionality (responses to two binary-choice WTP questions 
for two different risk reductions must be consistent with the 
requirement that WTP is less than but close to proportional to the 
magnitudes of the risk reductions). The survey was designed such 
that accepting both offered risk reductions at the offered WTP 
amount, or rejecting both offered risk reductions at the offered WTP 
amount, counted as consistent, whilst accepting one and rejecting 
the other counted as inconsistent. The authors acknowledge that 
satisfying this criterion is a necessary, but not sufficient, condition 
for being close to proportional in WTP. Only 42% of respondents 
passed this test leading to the exclusion of a total of 58% of the 
sample in the most restrictive analyses. In Alolayan et al. (2017), 
where the consistency test was originally introduced, 16% of the 
sample was excluded using the same criteria. Whereas as 
described, previous studies using the direct elicitation approach 
have encountered issues on the individual level, several studies have 
found that on the aggregate (across individuals), estimated WTPs 
are near proportional to the reduction in probability of illness which 
is in accordance with theory see (Hammitt and Haninger, 2017; 
Hammitt and Haninger, 2010). Still, the issue that a large number of 
respondents do not meet the scope sensitivity consistency check 
on the individual level, raises validity concerns about the use of the 
direct elicitation method.
The second issue is that a direct elicitation of WTP would require 
information or assumptions about individual health states to provide 
an empirical link to the WTP-QALY (Section 2.2 below).
Setting these two issues aside, a recent study (Balmford et al., 2019) 
comparing the validity of the chained method and the direct method 
concluded that the former generated more reliable estimates of an 
adult VPF. However, child VPFs were also elicited but results were 
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inconclusive with respect to the validity of both the direct and the 
chained methods. A conventional standard gamble was used in the 
Balmford et al. (2019) paper which has been shown to be vulnerable 
to a ‘certainty effect’. A modified standard gamble was developed 
for the Carthy et al. (1999) to ameliorate the ‘certainty effect’. Thus, 
two of the unresolved issues with respect to the chained method in 
that study (valuation with respect to children and the reliability of a 
conventional standard gamble) do not obviously apply to the 
chained method as proposed in the conceptual framework (Section 
2) although of course other validity issues may arise and are 
considered in Section 3.
Finally, as discussed in RQI, a VOLY and WTP-QALY can be derived 
from existing VPF estimates (see Mason et al. 2008 for a review) as 
well as RQI and RQV for a discussion). However, this raises similar 
concerns as above with regards to scope insensitivity and 
assumptions regarding health states. In addition, preferences might 
differ significantly across health care and traffic safety which led 
Mason et al. (2008) to conclude that this would not be a suitable 
way of estimating WTP-QALY. Also, as explained in Mason et al. 
(2009), there are two variants of deriving a VOLY and WTP-QALY 
from a VPF depending on whether all affected individuals enjoy the 
same risk reduction or individuals enjoy the same gain in life 
expectancy. As discussed in Mason et al. (2009), only in exceptional 
circumstances will the two be equal. The proposed framework 
allows for an estimation of both.
It turns out, though, that by adapting existing empirical methods 
from the VPF and WTP-QALY literature, an empirical method for 
calculating a VOLY can be proposed, one that is compatible with the 
conceptual framework below. Combined, this means that any new 
primary research would be underpinned by significant conceptual 
and empirical advances, offering substantially more robust values 
for future policymaking.
 2.1.3 Proposed framework: conceptual and empirical advances
An important issue not raised so far is the fact that the approaches 
underpinning VOLY and WTP-QALY elicitation have been developed 
from different methodological traditions relying on different 
assumptions (see Hammitt (2002) for a discussion). Whilst the two 
approaches do to some extent borrow methods and data from each 
other, the conceptual links are not yet well developed. The purpose 
of the next sub-section is to fill this gap by setting out a framework 
for the empirical elicitation of the value of life expectancy gains in a 
manner compatible with a WTP-QALY. In this framework, a VOLY is 
consistent with the conceptual foundations of the one-period VPF 
model underpinning current HM Treasury advice (Green Book, 2018) 
for valuing the prevention of immediate fatalities and also has a 
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clear link to a monetary value of a QALY. Thus, when applied 
empirically, the same methodology could be used to estimate a 
VOLY, a VPF or a WTP-QALY.
Empirically, the framework avoids the elicitation issues outlined 
above since it breaks the valuation task down into two stages, each 
of which is designed to be cognitively manageable for respondents. 
A respondent’s value of a gain in life-expectancy is then derived by 
‘chaining together’ his/her responses to the questions posed in the 
two stages. Thus, empirically, the method adapts the approach used 
to derive the current VPF (Carthy et al., 1999) to a VOLY context. The 
chained approach has also been used to derive a usable set of data 
in the context of a WTP-QALY (Robinson et al., 2013).
Thus, in principle this framework could be deployed without any 
further conceptual development (over and above that outlined in the 
next sub-section). Empirically implementing the framework in the 
VOLY context would require intensive piloting to identify and 
mitigate any potential problems (see Section 3). The next sub-
section sets out this framework.
 2.2 Conceptual framework for eliciting a VOLY and/or 
WTP-QALY
The conceptual framework is grounded in the formal specification of 
a VOLY outlined in the Technical Appendix and RQV and hence a 
VOLY can be considered as;
‘Aggregate willingness to pay, summed over a large group of people, 
for marginal reductions in the hazard rate for the coming year (or 
some future year or years) where, taken over the group of people 
affected, the marginal gains in remaining life expectancy generated 
by the hazard rate reductions sum to one year’.8
This definition establishes the close relationship between the VOLY 
and the VPF. Both measures are underpinned by the assumptions of 
Expected Utility Theory and are based on individual WTP - based 
values for small risk reductions which are aggregated over a large 
group of individuals in two different ways for use in policy. The link 
between the VOLY/VPF and the WTP-QALY will be described later but 
in the context of the VOLY and the VPF, the relationship is as follows;
	 Gains in life expectancy can only be generated by small mortality 
risk reductions. These are valued using WTP.
	 The VPF represents the aggregate WTP-based value of small 
individual mortality risk reductions which, taken over the affected 
8 As the CBA framework sums values across the relevant population we follow this convention and present 
the basic presentation of the VOLY on the aggregate level which is also in line with the UK definition of VPF, 
see the discussion in Jones-Lee et al. (1985). 
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group of individuals, can be expected to prevent one statistical 
fatality/save one statistical life (not the value of saving an 
identified life). Similarly, the VOLY represents the aggregate WTP-
based value of small individual gains in life expectancy which, 
taken over the affected group of individuals, sum to one year (not 
the value of one individual’s life year). As such, the VOLY 
represents the value of a ‘statistical’ life year.
Based on the above, it is clear that the relationship between WTP 
(which reflects the value of the gain in lifetime expected utility 
generated by the change in hazard rate) and a change in life 
expectancy must be established as part of this framework. In the 
Technical Appendix and RQV, it is established that expected utility 
increases in proportion to the size of the gain in life expectancy 
implied by the change in hazard rate. However, once diminishing 
marginal utility of wealth is taken into account this linearity no longer 
holds by definition i.e. the increase in WTP is no longer proportionate 
to the life expectancy gain, in that WTP for a 3-month gain would be 
expected to be less than 3 times that for a one-month gain9. Hence, 
the relation between an individual’s WTP and his/her gain in life 
expectancy i.e. WTP = f(∆E) - where ∆E represents a change in life 
expectancy - will take the following form (Figure 1)10:
Figure 1  Relationship between WTP and gains in life expectancy (LE)
9 For this discussion we focus on marginal utility of wealth. See RQV for a discussion of whether health 
status impacts on the marginal utility of income (consumption).
10 Under the assumption that, at the origin, the function is well-behaved (continuous and twice differentiable) 
so that, at the origin, WTP is equal to willingness-to-accept (WTA). If, instead, preferences were reference-
dependent, the function would be ‘kinked’ at the origin and marginal WTA would be greater than marginal 
WTP. However, evidence that does exist in the context of non-serious health states, suggests that there is 
no strong evidence available to reject the hypothesis of ‘smooth’ preferences (Chilton et al., 2012).
WTP
Gain in LE
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Life expectancy gains delivered by public policies can be marginal 
or non-marginal. In the case of marginal gains, a very small gain in 
life expectancy is enjoyed by each member of a large group of 
individuals. Thus, suppose that each member of a large group of n 
individuals enjoys a gain of 1/n of a year of life expectancy so that, 
summed over the affected group, the aggregate gain in life 
expectancy is one year. As far as each affected individual is 
concerned, his/her WTP for the marginal gain will be given by the 
gradient of his/her WTP = f(∆E) function at the origin (the slope of 
the dotted line in Figure 1) multiplied by 1/n. Summed over the n 
affected individuals, aggregate willingness to pay will therefore be 
equal to the sum of 1/n times the gradient of each individual’s WTP 
= f(∆E) function at the origin which is, by definition, the arithmetic 
mean of the gradient for the affected group. It therefore follows that 
the VOLY for marginal gains in life expectancy for the group is given 
by the arithmetic mean of the gradient of each affected individual’s 
WTP = f (∆E) function at the origin.
Ideally, we would elicit individual’s WTP for extremely small gains in 
LE (very close to the origin). Due to issues of scope insensitivity (see 
above), that is likely to be problematic. However, given that the graph 
is constructed so as to pass smoothly through the origin, by 
estimating (at least) two points on the curve, the functional form of 
the curve can be estimated. To get an indication of the typical size of 
a marginal gain in life expectancy, the risk reduction in a typical VPF 
survey would, as mentioned, generate a gain in life expectancy of a 
few hours, or at most, days. The study by Alberini et al. (2006) found 
that a relatively large mortality risk reduction of 5 in a 1000 over the 
next 10 years corresponds to 37 days of additional life expectancy.
As far as the research team is aware, the large majority of policies 
that deliver risk reductions to the general population will deliver 
marginal gains, and for these it would be appropriate to use the 
approach outlined above. However, the method can also be applied 
to the case of non-marginal gains and is thereby more flexible. The 
Technical Appendix argues that in the case of non-marginal gains, it 
might be inappropriate to base the VOLY on the affected individual’s 
valuation of marginal gains (i.e. the gradient of the graph in Figure 1 
at the origin) as above and, instead, it may be more appropriate to 
base it on an individual’s WTP for a longer duration e.g. a 0.25 year 
(i.e. 3-month) gain in life expectancy. Diagrammatically, the VOLY 
would then be given by the arithmetic mean over the affected group 
of the slope of the chord (i.e. WTP/∆E) at ∆E (Figure 1 above). For 
example, in the case of a three-month gain in life expectancy the 
VOLY would be given by the arithmetic mean over the affected 
group of the slope of the chord, WTP/∆E, at ∆E = 0.25. In summary, 
by estimating the whole curve, policy makers are provided with the 
flexibility to adopt either approach i.e. a VOLY based on marginal or 
non-marginal gains in life expectancy.
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Turning to the relationship between the VOLY and WTP-QALY, the 
conceptual framework requires a mechanism to convert WTP for a 
non-fatal injury or a health state and chain this to an equivalent gain 
in life expectancy. This is known as the chained method. Note that 
the basic argument underpinning the chained approach is that it is 
simply a mechanism that links the answers to two separate 
questions together and in and of itself does not require the 
assumption of Expected Utility Theory.
Here, we present two different ways of relating different severities of 
non-fatal injuries/illnesses to gains in life expectancy. Both of the 
approaches are based on existing conventions presented in the 
literature and which are used for policy making (see Carthy et al. 
(1999) and Franklin (2015)). The novelty here is that, by keeping gains 
in life expectancy as the common denominator, we demonstrate how 
this framework for deriving a VOLY is compatible with the WTP-QALY 
framework. It is, of course, the case that the compatibility of the 
measures is affected by a number of additional considerations, in 
particular by discounting and by the distinction between normal 
versus perfect or full health, although the underlying fundamentals of 
the relationship remain intact. The two approaches are summarised in 
Figure 2 below11. We restrict the framework to a one-period hazard 
reduction and gains, rather than losses, in life expectancy12.
Figure 2  Conceptual link between Carthy et al (1999) and WTP-QALY as  
derived in Franklin (2015)
11 We have chosen to present the procedures summarised in Figure 2 to arrive at aggregated values rather 
than describing the utility functions underlying the individual decisions
12 Note that aversion to immediate risk can be accommodated within this framework (see Section 4 of this 
report and RQV).Extending this framework to willingness-to-accept (WTA) for losses in life expectancy is 
considered in the Technical Appendix 
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 2.2.1 Approach 1 (VPF and VOLY)
Approach 1 is set out in detail in the Technical Appendix. In 
summary, this approach is a modification of the Carthy et al. (1999) 
chained approach used to elicit the value of mortality risk reductions 
to estimate a VPF. This process is summarised in Figure 2 (the blue 
lines) and explained in detail in Carthy et al. (1999).
Here, we modify this method to instead elicit individual values for 
gains in life expectancy in normal health and, hence, to estimate a 
VOLY. The key difference here is that a modified Standard Gamble 
(SG) approach is used to elicit the loss in life expectancy that the 
respondent regards as being as bad as suffering a non-fatal injury H 
for a year13.
The procedure is as below;
	 Elicit WTP for quick and complete cure for suffering a non-fatal 
injury (H) for a year.
	 Elicit the loss of life expectancy in normal health (∆E) that is as 
bad as suffering the non-fatal injury or illness. The procedure is 
as follows;
	 Individual responses to a modified14 SG generate an estimate 
of π which is the maximum risk of treatment failure the 
individual would be prepared to accept in a treatment which, if 
successful, would result in an immediate and complete cure 
for injury H and returning to normal health for the rest of their 
lives. If the treatment was unsuccessful it would result in 
immediate death.
	 The π elicited from the exercise above is a one-period change 
in mortality risk. Multiplying π by remaining life expectancy i.e. 
(∆E) = πE allows a calculation of the loss in life expectancy in 
normal health that follows from π (see Technical Appendix). 
Hence a quick and complete cure for H yields the same gain 
in lifetime expected utility as a gain in life expectancy of πE in 
normal health. The estimated WTP (from step 1) is chained to 
the gain in life expectancy in normal health (from step 2).
Steps 1-4 are repeated with different severities of H and different 
gains in life expectancy (in normal health) can therefore be valued 
corresponding to different points on the valuation function i.e. 
VOLYs. Based on this, the rest of the valuation function (for smaller 
and larger life expectancy gains) in Figure 1 can be estimated using 
regression analysis (see the Technical Appendix for a simple 
13 Note that to illustrate, we use one year. This simplifies the equations included in Figure 1. However, the 
method can be adapted to use longer or shorter durations as well, where the latter would reduce any 
scope insensitivity arising due to budget constraints.
14 See Carthy et al. (1999) for rational for and outline of its development
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example or Alolayan et al. [2017] and Hammitt et al. [2019] for more 
discussion of how empirical estimates of income elasticity can be 
used to estimate the curve). Note that π elicited in step 2 can be 
chained to the WTP elicited in step 1 to estimate a VPF, see Carthy 
et al. (1999). Following the procedure above effectively ‘translates’ a 
complete cure for different severities of H into the equivalent gains 
in life expectancy in normal health, corresponding to particular 
points on the horizontal axis in Figure 1. The procedure above would 
enable a more robust valuation function (WTP = f(∆E)) to be 
established both at an individual and aggregate level, across a 
range of plausible life expectancy gains, both marginal and non-
marginal. The Technical Appendix uses data from the Carthy et al. 
(1999) study to illustrate the process in practice and finds 
approximate correspondence to the WTP-QALYs estimated in 
Franklin (2015).
 2.2.2 Approach 2 (WTP-QALY)
RQII describes how to estimate a WTP-QALY using the chained 
approach. Below, we outline how the Carthy et al. (1999) data and 
the UK EQ-5D tariffs (Devlin et al., 2018) for different EQ-5D health 
states can be used to estimate a WTP-QALY (further details on the 
EQ-5D descriptive system and tariffs can be found in RQIII). This 
follows the approach outlined in Franklin (2015) and corresponds to 
the red lines in Figure 2.
	 Elicit WTP for quick and complete cure for suffering a non-fatal 
injury (H) for a year.
	 The QALY loss associated with H is estimated by multiplying the 
time spent in health state H with the health state utility value 
associated with that health state. Following Franklin (2015), the 
health state utility value is estimated using the UK EQ-5D tariffs 
for different EQ-5D health states (Devlin et al., 2018).15
Step 1-2 is repeated with different severities of H. A valuation 
function can be derived and the associated WTP-QALY can be 
estimated. Using this approach, the valuation function will effectively 
be a function of gains in QALYs, which appears to be in contrast to 
Figure 1. Below, we show how an elicited health state utility value for 
a health state H - a health state with equivalent loss of quality of life 
to suffering non-fatal injury or illness H - can be translated into a 
change in life expectancy in perfect or full health using a Time 
Trade-Off(TTO)16 We therefore provide the link between Approach 1 
and Approach 2 (the red dotted line in Figure 2 above) and hence 
a WTP-QALY can be illustrated in Figure 1 as well as a VOLY 
and a VPF.
15 Note that the health state utility values could also be elicited in a new primary study (see Section3)
16 See Appendix in RQIII for a full description of SG and TTO approaches
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 2.2.3 Relationship between VOLY and WTP-QALY
As demonstrated below and in the Technical Appendix, the two 
approaches are intrinsically linked and as such, this framework is 
one way of integrating the VOLY and WTP-QALY measures, both 
conceptually and empirically. Whichever approach (1 or 2) is used, in 
the first stage an individual is asked for his/her WTP for a quick and 
complete cure for non-fatal injury H. At the second stage s/he 
provides a response that identifies the loss of remaining life 
expectancy (∆E) in normal - or full - health that the individual 
considers equally as undesirable as suffering non-fatal injury H. In 
this case, the maximum WTP elicited in stage one can also be taken 
to represent his/her maximum willingness to pay for a gain of ∆E 
years of life expectancy in normal – or full (perfect) - health. In this 
way, the individual’s responses to the WTP and SG (or TTO) 
questions can be ‘chained together’ to obtain an estimate of his/her 
WTP for a specific gain in life expectancy. By presenting the 
individual with WTP and SG (or TTO) questions for a number of 
different severities of non-fatal injury or illness it would then be 
possible to estimate his/her WTP = f(∆E) function (see Figure 1).
The conceptual link between VOLY and WTP-QALY is summarised 
in Figure 2 (illustrated by the dotted lines). Denote the utility of one 
year in perfect or full health by U and the utility of one year of 
suffering injury H by H17. If the individual in a TTO question indicates 
that suffering injury H for 10 years is equivalent to spending t years 
in perfect or full health, it follows that 10H = tU. This means that H/U 
= t/10 and one year of H would therefore be treated as yielding t/10 
QALYs. Likewise, it follows from the SG in Approach 1 (see 
Technical Appendix (eqn. 6)) that H/U = (1 – πÊ), where Ê denotes 
the individual’s remaining discounted life expectancy (computed 
using his/her personal discount rate. We will return to the issue of 
discounting in Section 2.2.4 below. Setting the distinction between 
normal and perfect or full health aside for now (see Section 2.2.4.), if 
the individual answers both the SG question (in Approach 1) and 
TTO questions (in Approach 2) in a manner that conforms with 
expected utility, then it will necessarily be the case that H/U = t/10 = 
(1 - πÊ). This means that the loss of life expectancy equivalent to 
suffering the non-fatal injury or illness for one year implied by the 
response to the SG question (i.e. πÊ) will be equal to the loss of 
discounted life expectancy equivalent to suffering the non-fatal 
injury or illness for one year implied by the response to the TTO 
question (i.e. 1 – t/10) as defined in the Technical Appendix, eqn. 7. 
Note also that SG has been used to elicit health state utility values 
used in the calculation of QALYs in the literature (see RQIII) and 
hence a SG could, in principle, be used in both Approaches 1 and 2. 
17 Full health might be considered as perfect health, as defined by the particular health utility measurement 
scale applied e.g. for EQ-5D it is (1,1,1,1,1) (see RQIII).
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For the purpose of simplifying the presentation of this framework 
here, we have chosen to focus on the TTO as it was used to 
estimate the health state utility values for different EQ-5D health 
states (EuroQoL Group, 1990) that are recommended for use by the 
National Institute for Health and Care Excellence in the appraisal of 
new health technologies (NICE, 2013). The SG presented under 
Approach 1 differs from the one traditionally used to elicit health 
state utility values on two key aspects; 1) respondents are informed 
that they will return to perfect or full health, whereas in the chained 
approach respondents are informed that they would return to 
normal health. The distinction between perfect or full and normal 
health might be expected to ‘pull’ the two measures of the value of 
the same gain in life expectancy apart, an issue on which we will 
elaborate on later, and 2) in the chained approach, preferences are 
elicited for avoiding H which is a temporary health state (e.g. one 
year). Traditionally, when health state utility values have been elicited 
to be used in QALYs, preferences have been elicited for a chronic 
health state which will be ongoing over the rest of the individual’s 
life, see Appendix to RQIII. In this case, as time is held constant 
across the three states (perfect health, death and chronic illness), 
the QALY weight (H/U) is elicited as (1-π) and life expectancy (E) 
cancels out (see Technical Appendix Eqn. 6).
However, there are some further issues to be considered. Figure 2 
illustrates the relationship between WTP and gain in life expectancy 
when the gain in life expectancy is undiscounted. Further, as noted, 
the framework has not accounted for the difference between full or 
perfect and normal health (which is an artefact of two different 
methodological conventions within the two different contexts (health 
economics (QALYs) and safety economics (WTP)). These two issues 
are discussed below.
 2.2.4 Discounting and issues relating to full/normal health
Prior to setting out a more formal framework with respect to 
discounting life expectancy (below) we first provide an intuitive 
explanation. Essentially, the value of a gain in life expectancy will be 
determined by the resultant gain in the discounted present value 
(computed at personal discount rates) of the stream of future annual 
expected utilities of affected individuals. This means that if a gain in 
undiscounted life expectancy is the result of later hazard rate 
reductions then it will be accorded a lower value than the same gain 
in undiscounted life expectancy generated by earlier hazard rate 
reductions. In order to accommodate this effect, it would seem 
sensible to define the VOLY on the basis of gains in appropriately 
discounted life expectancy.
For example, when we calculate the VOLY from individuals’ 
aggregated stated willingness to pay for a gain in undiscounted life 
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expectancy, we divide the stated aggregate WTP amount by the 
undiscounted life expectancy gain as a proportion of 1 year (e.g. if a 
6-month gain is worth £10,000, we divide WTP by 0.5 to get a VOLY 
of £20,000). However, WTP values will actually be based on 
discounted utility, and an X-month objective gain in life expectancy 
is equivalent to a gain of less than X months in discounted life 
expectancy. For instance, a 6-month objective gain in life 
expectancy may equate to a 4-month gain in discounted life 
expectancy. In this case, to calculate the VOLY, we must divide 
£10,000 by (1/(1/3)), so the VOLY is £30,000. From this, it is clear that 
ignoring discounting means that the VOLY will be underestimated.
As explained above in Approach 2, a TTO-based QALY associated with 
an injury/illness is defined as a fraction of a year in full health that yields 
the same utility as one year suffering that same injury/illness. Let us 
denote utility of one year in full health by U and utility of one year spent 
suffering injury/illness by H. It therefore follows that the loss of life 
expectancy equivalent to suffering the injury/illness for one year implied 
by the TTO-based QALY-loss associated with the injury/illness is the 
fraction of a year in full health which, if subtracted from remaining 
survival time, would imply a utility loss of U – H. Approach 1 is based 
on a SG-based elicitation of the maximum probability of treatment 
failure, π, that he/she would accept for a treatment which, if successful, 
would result in an immediate cure for the injury/illness lasting one year, 
but if unsuccessful would result in immediate death. Thus, if the loss of 
life expectancy equivalent to suffering the injury/illness for one year 
implied by the response to the SG question is to be equal to the loss of 
life expectancy implied by the TTO-based QALY-loss, then the loss of 
lifetime expected utility resulting from an increase, π, in the probability 
of immediate death must be equal to U – H. But, by definition, an 
individual’s remaining lifetime expected utility will be the discounted 
present value of future annual utilities computed using his/her personal 
rate of time-preference. In addition, when answering the SG question in 
Carthy et al. (1999), the respondents were asked to imagine that he/she 
will spend the rest of life in normal (rather than full or perfect) health. 
Thus, if the loss of life expectancy derived from the response, π , to the 
SG question is to be equal to the loss derived from the TTO-based 
QALY for the injury/illness concerned then a) the loss of life expectancy 
implied by the SG response will need to be computed as the product 
of π and discounted remaining life expectancy and b) the loss implied 
by the SG response in Carthy et al. (1999) will require further downward 
adjustment to take account of the fact that the TTO-based QALY-loss 
is a loss of survival time in full or perfect health, whereas the SG 
response in Carthy et al. (1999) is based on the assumption that the 
rest of life will be spent in normal health.
Clearly then, if the VOLY is derived using Approach 1 by chaining 
WTP for a complete cure for one year of the injury/illness to the 
SG-based estimate of the loss of life expectancy judged to be 
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equivalent to suffering the injury/illness for one year - with the latter 
subjected to appropriate discounting and further downward 
adjustment to take account of the full health/normal health 
distinction - then the resultant VOLY should be equal to the WTP-
based value of a QALY derived by chaining the WTP response to 
the TTO-based QALY-loss associated with suffering the injury/illness 
for one year. Derived using discounted life expectancy and 
subjected to an appropriate full health/normal health adjustment, a 
SG-based VOLY should therefore be equivalent to the valuation of a 
TTO-based QALY.
To get an indication of the magnitude of the effect of discounting, 
assume, as in Technical Appendix, that average remaining life 
expectancy is 40 years. Applying, for illustrative purposes, a 
personal discount rate of 6%, the 40 years can be converted to 15 
discounted life years which are then multiplied by the change in 
mortality risk, π to get the (discounted) gain in life expectancy18. 
Jones-Lee et al. (2015) note that, if gains in life expectancy are 
computed on a discounted basis using the personal rate of time 
preference, then under reasonable assumptions concerning the 
pattern of anticipated future annual utilities, the VOLY will be 
completely independent of whether the risk reduction that gives rise 
to the gain in discounted life expectancy occurs in the current year 
or is instead on-going over a person’s lifetime. This, together with 
the argument developed above concerning the appropriate 
interpretation of TTO-based QALY losses and SG results, provides a 
rather persuasive case in favour of defining a VOLYd i.e. on the basis 
of gains in discounted life expectancy. Similar to the VOLYd, an 
argument for discounting can be made for WTP-QALY i.e. WTP-
QALYd. Due to the difference between normal and perfect or full 
health noted above, the individual’s WTP-QALYd (estimated as the 
gradient of the valuation function) will be steeper than the VOLYd 
and hence WTP-QALY will be higher than the VOLY.
 2.3 The Carthy et al. (1999) data set
In the Technical Appendix, we utilise the Carthy et al. (1999) data set 
to illustrate how the framework would underpin both an estimate of 
a VOLY and a WTP-QALY in addition to the VPF reported in the 
original study. As such, an argument could be made to use this data 
set to estimate a VOLY for use in current and future regulatory 
analysis, not least since it would generate a VOLY based on the 
same preferences elicitation as the current VPF. However, caution is 
merited in considering this approach for the following reasons:
18 The 6% rate used in this example is in line with much of the empirical literature (see RQIV for details). 
However, we recommend the elicitation of personal rates of time preference on an individual level in any 
new empirical research.
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	 The data for the Carthy el al. (1999) study was collected in 1997 
and is therefore more than 20 years old;
	 The estimates were based on a small initial data set of 167 
respondents; which was trimmed to a final, usable data set of 
135 respondents;
	 Only two different injuries were used for the elicitation (X and W). 
To derive the full curve (Figures 1-2 above), valuation of other, 
non-marginal changes in life expectancy would be needed to 
generate a reliable value function;
	 The Carthy et al. (1999) study used a one-time payment to avoid 
non-severe injuries (which, as noted, equate to relatively smaller 
life expectancy gains). Such a payment vehicle would imply 
significant budget constraints impacting on the valuation of non-
marginal injuries (which would equate to larger life expectancy 
gains) and hence a more appropriate the payment vehicle of 
on-going payment over, for example, 5-10 years would be 
preferable, with appropriate adjustment to account for 
discounting (see RQII for further discussion of payment vehicles).
On a related note, the Chilton et al. (2004) study does in fact 
provide three points on a VOLY value function i.e. values for 1 
month, 3 months and 6 months additional life expectancy. 
However, due to its incompatibility with the above framework, a 
WTP-QALY could not be derived. In addition to other limitations 
(see RQII) and the increasingly dated nature of the resulting 
information, this precludes recommending the widespread 
adoption of a VOLY based on this study.
In summary, the proposed framework makes clear the conceptual 
link between the three measures used to value reductions in risks to 
life and health. Adopting a ‘context-less’ or ‘generic’ VOLY (see 
RQIV and Section 3 for a discussion) underpinned by this framework 
maintains the current flexibility that Government Departments have 
to value the type of life expectancy or health outcomes delivered by 
their own policies.
 2.4 Outstanding Considerations
Nevertheless, there are some outstanding issues, some of which are 
addressed in Section 2 and 3 and others that would require to be 
accommodated or addressed within any primary research 
employing this framework.
	 The current approach is based on a one-period model. This has 
some advantages, not least that the current VPF could also be 
updated to reflect current preferences, and that a WTP-QALY 
can be estimated. However, it does mean that the potential exists 
for the VOLY to be underestimated for those respondents who 
have higher values for (equivalent) life expectancy gains 
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generated by on-going risk reductions. The degree of bias 
depends on how significantly estimates of π differ between these 
respondents and those that would strictly prefer their life 
expectancy gain to be generated from a one-period risk 
reduction (RQV). This issue could be addressed by employing a 
relative valuation method to identify the necessary adjustments to 
the value of life expectancy gains generated from on-going risk 
reductions relative to the value elicited for one-period reductions.
	 The problem posed by the inherent inconsistency of a constant 
VOLY and constant VPF (RQV) if deployed in policy remains. This 
is considered later in Section 4.
	 Much is yet to be learned about respondents’ understanding of 
how life expectancy gains are generated from small changes in 
the underlying hazard rate–as well as their comprehension of 
value elicitation questions per se. Whilst the latter is covered 
using best-practice survey design procedures which include 
cognitive testing, the latter would seem to require a directed, 
in-depth qualitative investigation, the results of which may also 
assist in the interpretation of the aggregate quantitative data.
	 Behavioural biases are not included in the above framework. In 
particular, if non-standard discounting (i.e. non-exponential 
discounting, or time preferences that imply inconsistent choices 
over time) prevails at the level of the respondent, then it would be 
necessary to account for each respondent’s personal discount 
function, as well as their personal rate of time preference, when 
calculating the discounted gains in life expectancy.
	 The purpose of the framework is not to identify categories of 
practical application for which the VOLY (as distinct from the VPF 
or the QALY) is to be preferred.
Section 3 now follows in which the associated empirical procedures 
are considered in more detail.
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3 An empirical study for the VOLY, 
VPF, and WTP-QALY
This section will describe the required scale and appropriate 
methodology necessary to deliver a set of empirical estimates under 
the framework described in Section 2, one that allows the three 
monetary values: VOLY, WTP-QALY and VPF to be estimated from 
the same data set.
To recap, in order to operationalise the conceptual framework, and to 
estimate a VOLY, an empirical approach is required that chains a gain 
in life expectancy to Willingness to Pay (WTP) for this change in life 
expectancy. We propose the use of Standard Gamble (SG) and Time 
Trade-off (TTO) to estimate the change in life expectancy to ensure 
the elicitation procedures reflect the conceptual link in Figure 2.
The chained approach is not new, as presented in RQI and RQIII, a 
number of studies have been developed over the past 20 years which 
have chained a WTP estimate with a health state (via a SG or TTO) 
(Carthy et al., 1999; Robinson et al., 2013; Baker et al., 2010). However, 
the manner in which the estimates of WTP and SG/TTO are combined 
to calculate the VOLY is novel. Further, if discounted life expectancy is 
used, this eliminates the need (for policy purposes) to calculate the 
value of life expectancy gains arising from other perturbations of the 
underlying survival function and incorporates the recent theoretical 
developments with respect to discounting into the estimation process.
Many aspects of the design will be unique to a particular survey and 
so cannot be considered here. One important issue that is difficult to 
be prescriptive on is whether it is possible (or even desirable) to elicit 
a ‘context free’ measure. This is considered in more detail in (RQIV). 
We simply note here that the definition of ‘context’ is multi-faceted 
and can include almost anything. The evidence in the literature is 
such that it would be difficult to identify specific contextual features 
that can be expected to systematically affect a VOLY.
We prefer the term ‘generic’ VOLY instead, meaning a value that is 
not specific to a particular scenario description/risk reduction. This 
maximises the tractability of the measure for policy use and means 
it is not affected by features specific to a particular domain that 
might not be relevant in another. Mason et al. (2008) specifically 
raised this concern with respect to using preferences for traffic 
safety in the context of health care. By definition then, the domain 
(e.g. road; air pollution; food) would be left unstated in the survey; 
however, if difficulties arise in respect of realism/acceptability in the 
piloting phase, a domain may have to be introduced.
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 3.1 Survey design
The survey is designed around SG/TTO and corresponding WTP 
questions relating to health states or injuries to generate sufficient 
data points to estimate the value function as outlined in Section 2 
(Figure 1). Ideally, each respondent would provide responses to the 
three types of questions for three to five points on the curve 
representing health states or injuries of different levels of severity 
(and hence differing life expectancy gains). If piloting suggested that 
this was too many questions for an individual, a split sample design 
could be deployed (WTP and SG; WTP and TTO) and the aggregate 
responses combined.
As outlined in RQIII, both the SG and TTO have been successfully 
used in the elicitation of WTP-QALY (Robinson et al., 2013; Baker et 
al., 2010). In this study, the SG and TTO are used to link WTP to 
avoid the suffering associated with a non-fatal injury or health state 
to a change in remaining life expectancy and not as a measure of 
the health-related quality of life of the health state. However, the 
design and application of these questions should still take account 
of best practice. For example, using visual aids alongside a written 
explanation of the choice task (see Attema et al., 2013 and Brazier 
et al., 2017 for a discussion of best practice for each approach).
For a survey based on the framework outlined in Section 2 the 
contingent valuation method (CVM) would provide the most direct 
way to elicit individual WTP19. This would be in accordance with the 
chained approach adapted in Carthy et al. (1999) and Robinson et 
al. (2013). As with SG and TTO questions, current best practice 
should be used for the design of standard contingent valuation 
survey features, such as the payment vehicle, including duration of 
payment and elicitation method (see Johnston et al., 2017) for 
further discussion). The payment vehicle is non-neutral but should 
be compatible with the way in which the scenario is presented to 
respondents, for example justification should be made for selecting 
either out of pocket payments, changes in taxation or general cost 
of living. Alternative payment vehicles are discussed in more detail 
in RQII and would require different payment structure to the one 
suggested here e.g. recurring payments for the rest of a 
respondent’s life.
The framework proposed in Section 2, relies on a (next) one period 
risk reduction, and thus the timing of the payments should also be 
in the same one period. This does not preclude a series of 
payments within that period – such an approach might be 
advantageous as it could reduce, or eliminate, the potential problem 
19 Note that the framework does not preclude other stated preference approaches to elicit the WTP 
component of the ‘chained method’.
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that budget constraints may severely limit WTP. To elicit WTP values 
from respondents, elicitation mechanisms with proven weaknesses, 
such as payment scales which can suffer from range bias, should 
be avoided.
As the overall validity of the chained approach relies on the quality 
of the data in response to both the SG/TTO and the WTP questions, 
we have identified three key methodological issues to consider 
during the design of a chained study. The first two arise because of 
the potential impact of the ‘anchoring and adjustment’ heuristic 
(Tversky and Kahneman, 1974) that affects stated preference 
techniques in general20. The third issue is a potential artefact of the 
chained method itself.
 3.1.1 Scope insensitivity
The problem of scope insensitivity was in fact the major motivation 
for the development of the chained approach (Beattie et al., 1998; 
Carthy et al., 1999) that underpins the conceptual framework 
outlined in Figure 2. Scope insensitivity in the estimation of the 
VOLY relates to whether WTP values change in proportion to the 
size of life expectancy gain or risk reduction. As outlined in RQII, a 
number of methodological developments have been made within 
stated preference methods over the past 10 years to reduce the 
problem of scope insensitive WTP responses. In this particular 
context whilst risk communication remains a challenge - some 
recent developments could in principle be tested and incorporated 
to reduce the impact of imprecise preferences over risk and/or 
cognitive difficulties on the proportionality of WTP to the different 
risk reduction.
There are two further elements that can cause scope-insensitivity 
and hence non-linearity in the valuation function; budget constraints 
and diminishing marginal utility of wealth. It is possible to design an 
instrument that avoids the impact of budget constraint and minimises 
the impact of insensitivity to the magnitude of the risk reduction by 
choosing appropriate points on the valuation curve (see above). 
However, it is not possible to isolate and quantify the impact on the 
slope of the valuation function of diminishing marginal utility of 
wealth21 as it will be conflated by the two other elements. In addition, 
whereas scope insensitivity and budget constraints are problematic 
with respect to elicitation of WTP, diminishing marginal utility of 
wealth is not. Thus, as Figure 1 illustrates (and further expanded in 
20 Anchoring and adjustment’ refer to situations in which ‘people make estimates by starting from an initial 
value, which may be suggested by the formulation of the problem, and then adjust that value to yield the 
final answer’ (Mitchell and Carson 1989, p. 115)
21 Note that while information on respondent’s income should be obtained as a matter of course in the 
demographics section of a survey, this cannot be used to estimate this impact. The main purpose of this 
variable is to test the economic consistency of WTP i.e. WTP should increase with income.
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the Technical Appendix) due to diminishing marginal utility of wealth 
it is expected that an individual’s WTP for a gain in life expectancy 
will not be linear i.e. proportional to the magnitude of the increase in 
life expectancy; instead an individual’s WTP will increase at a 
decreasing rate. This is not unique to life expectancy gains and is 
predicted by theory to apply generally across domains22.
 3.1.2 Non-traders or excess traders
In earlier studies designed to elicit a VOLY non-traders - 
respondents who refuse to take any risk of death however small for 
a proposed health gain in the SG question - have comprised up to 
approximately 20% of the sample (Alberini et al., 2010; Chilton et al. 
2004). However, the direction of travel in terms of the percentage of 
non-traders is encouraging as in the more recent European Value of 
a QALY (EuroVaQ) study non-traders were substantially lower i.e.3-
5% for SG and 7-11% for TTO (Robinson et al., 2013).
To deal with non-trading in the SG, the traditional strategy has been 
to present people with smaller risks of death e.g. 1 in 1,000, 1 in 
10,000, in the hope that they will trade. However, when combined 
with WTP to estimate a VOLY or WTP-QALY this can result in 
extreme values. For example, in the Social Value of a QALY study 
the options presented were 1 in 100, 1 in 1,000, 1 in 100,000; and 1 
in 1,000,000; 28% of respondents were only willing to take a 1 in 
100,000 risk of death in a standard gamble question, implying WTP-
QALY values in excess of £1million (Baker et al., 2010).
To address this problem, in a subsequent study (EuroVaQ 
(Donaldson et al., 2010)) risk was expressed in a more gradual way 
(1 in 100; 1 in 200; 1 in 300; 1 in 500 and 1 in 10,000) than in the 
SVQ study (1 in 100; 1 in 1,000; 1 in 100,000; and 1 in 1,000,000). 
This appears promising but would need further testing in the piloting 
phase of an empirical study to ensure that responses are not an 
artefact of the methods/options and instead that they represent a 
reliable reflection of respondents’ preferences.
A key consideration in the design of the scenarios necessary for this 
framework will be to identify a set of health states or injuries to be 
used in the survey. This will require significant attention in the 
piloting stage to ensure that the severity of these injuries or health 
states are such that respondents will be willing to take some risk of 
death (SG) or sacrifice some time in perfect or full health (TTO) and 
also be willing to pay to avoid the impaired health state. For 
example, if the scenario described a very minor injury like a broken 
finger, many respondents are unlikely to take a risk of death in the 
SG to avoid this minor injury even if they would be willing to pay to 
22 Although this is consistent with what we would expect, theory has nothing to say about the magnitude of 
this effect and whether this might be expected to vary across domains.
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avoid it. Alternatively, if the injury was very severe e.g. paraplegia, 
respondents are likely to take a risk of death on the SG but would 
be budget constrained in the WTP question.
This is important because it demonstrates that there will be 
empirical limitations to how much of the curve can be elicited and 
non-traders and budget constraints combine to set those limits. It 
may be difficult to identify three to five temporary health states that 
meet the requirements outlined. However, there are examples of a 
range of temporary health states being used in TTO and SG studies 
outside the VPF/VOLY/WTP-QALY literature that would serve as a 
starting point (see Stoniute et al. 2018; Oqwulu et al. 2017). As noted 
in Section 2.2.1, while the method outlined in Figure 1 is illustrated 
using a duration of one year, the chaining approach can be used 
with different durations as well as different levels of severity. This 
offers the potential of identifying the same point on the curve using 
different chains, serving to test the validity of the chaining approach 
(see below). The decision of what scenarios to use is an issue to 
investigate in the piloting phase.
Choice of appropriate health states is a necessary but not sufficient 
condition to the successful elicitation of points on the valuation 
curve. The difficulties that people have in understanding risks, in 
particular very small risks are well-documented elsewhere, but a 
general consensus has evolved in the mortality risk valuation 
literature with respect to this. To ensure respondents correctly 
interpret the probabilities in the SG exercise, it is important to 
incorporate a risk communication exercise, most usually risk grids in 
which respondents are shown for example a 100 square grid, with a 
small proportion of shaded squares to convey visually a 
respondent’s risk of dying (Robinson et al., 2013). This exercise 
should be interactive if possible, allowing respondents to make 
choices and receive feedback, to test comprehension before the 
start of the exercise.
Even with risk communication prior to the start of the exercise, 
significant problems may still arise from the complexities in the risk-risk 
trade off required in the modified SG question, developed in Carthy et 
al., (1999). These concerns, which were investigated during piloting, led 
directly to the decision in the SVQ studies (Baker et al., 2010) and the 
Valuation of Environment-Related Health Risks for Children study 
(Alberini et al., 2010), to not take it forward and instead to use a 
conventional SG where the comparator is a certain outcome23.
23 Having said that, Balmford et al. (2019) reported that the child VPF (relative to a parental VPF) elicited using 
a chained approach was much larger than might be expected based on the literature. They speculated 
that this might be due to double counting whereby a parent is both WTP a larger amount and take smaller 
risk of a bad outcome for their child relative to themselves. By chaining these preferences together the 
‘premium’ is included twice. It is an open question as to whether ‘certainty’ effect dominates or not the 
double counting effect, if present.
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However, more recent attempts at communicating risks have 
focussed on the wider information set in the scenario and have 
shown that it is possible to harness ‘spillover’ effects from 
incorporating incentivised decision-making experiments in a 
’learning’ phase prior to the valuation phase. Nielsen et al. (2010) 
showed that it was possible to establish valid preference rankings 
over different probability distributions generating the same gain in 
life expectancy. Nielsen et al. (2018) reduced the number of non-
traders by employing a pre-survey learning experiment in which 
respondents make incentivised risky choices and also using a frame 
that focuses on the total risk or risks that respondents face.
Our conclusion is that the combination of increased validity of 
responses (e.g. EuroVaQ) and improvements in design of the 
information set (“spillovers”) – both of which have been shown to 
reduce the number of non-traders - are sufficient methodological 
advances that should be harnessed to minimise the impact on the 
central tendency measures and to reduce number of responses 
trimmed from the data set to less than 10%.
However, researchers should not be complacent with respect to 
the challenges involved in incorporating such advances into a new 
study. Thus, new testing of this method should be conducted in 
the piloting phase to establish whether these new methodological 
developments can be incorporated and reduce the problem of 
non-trading.
 3.1.3 Interactions in the chaining process
A further caveat relates to the feasibility of chaining health states 
using the SG approach. Doing so relies on the assumption that 
“indirect” and “direct” estimates of the utility of a health state are 
equivalent. However, there is some evidence in the health 
economics literature that indirect estimates of the utility of a health 
state are higher than direct estimates (Llewellyn-Thomas et al., 
1982; Rutten-van Molken et al., 1995; Bleichrodt, 2001; Oliver, 
2003). Similar findings have been reported in the VPF literature 
(Carthy et al., 1999; Balmford et al., 2019) and lotteries (Chilton and 
Spencer, 2001).
By design, the chained approach must link together a response 
from a WTP question with a response from a TTO or SG question. If 
there is error within the responses to either (or both) of the 
questions, there is the potential for the resulting VOLY estimates to 
be inflated (an issue driving the Spackman et al., 2011 
recommendation for further testing of the method in the context of 
the VPF). Individuals may have imprecise or uncertain preferences, 
particularly for non-market goods (Dubourg et al., 1997; Butler and 
Loomes, 2007). Thus, it is recommended that approaches which 
account for uncertain preferences, such as Range-WTP are piloted 
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during the design of the survey (Braun et al., 2016). At the very least, 
it implies that, the number of health states/injuries chained together 
should be kept to a minimum24.
Each of these methodological issues have been presented 
separately here but, as noted, some of the solutions could be used 
to address more than one issue, for example, risk communication 
can reduce problems of insensitivity to scope and non-trading. 
Nevertheless, and as with all empirical methods, there are 
outstanding issues which have not yet been resolved in the literature 
on the chained approach. It is strongly recommended that any 
future study conduct an extensive pre-piloting phase to examine 
these issues before commencement of a large scale nationally 
representative study.
If, as recommended, estimates of the VOLY are based on 
discounted life expectancy then there are a number of options 
regarding the discount rate to use, which are outlined in Section 4.4. 
To elicit personal discount rates would require an extension to the 
current experimental design i.e. values for one-period risk 
reductions would be elicited for the coming year and for future years 
e.g. 5 years, 10 years (see McDonald et al., 2016 for an example of 
such a design in the context of latent cancer risks).
 3.2 Qualitative Pre-Testing
It is essential that the design and development stage of any new 
study includes qualitative methods, such as cognitive interviews, 
with members of the public to ensure respondent comprehension of 
the exercise. This is standard ‘good practice’, but there are a 
number of approaches that might be used. In this case, the 
proposed elicitation methods are relatively well established so the 
focus of qualitative developmental work should be respondents’ 
understanding and interpretation of the injury / illness scenarios, 
explanation of risk, presentation of WTP and SG questions, and 
time preference questions. Since there is a literature to draw on 
(Baker et al., 2014a; Chilton and Hutchinson, 2003; Baker and 
Robinson, 2004; Coast, 2017), any piloting should build on that work 
and focus on understanding of the ‘bespoke’ aspects of this study, 
the appropriateness and acceptability of presentational format and 
language, and limitations in terms respondent burden/fatigue. 
Concurrent ‘think-aloud’ techniques followed by brief interviews to 
follow each pilot survey would be appropriate (Coast, 2017). The 
qualitative pilot work should also seek to identify (and ‘design out’ 
24 In addition, this issue could be further investigated in the context of exploring the impact of different 
interim health states to arrive at a particular point on the valuation function.
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where possible) issues that have arisen in previous studies, such as 
non-traders in health or wealth.
Beyond the development of the questionnaire, it would be instructive 
to have a subsample of main study respondents (n=approx.50) 
complete valuation questionnaires together with ‘think–aloud’ 
techniques, immediately followed by brief qualitative interviews. 
Although the methods are the same as above the purpose and 
interview schedule would be different in this subsample, the 
purpose of which would be to investigate the construction of values 
and the rationales given by respondents for their values. This will be 
useful data to support and interpret quantitative findings and would 
ideally be conducted after a preliminary analysis of early survey 
completions. Respondents might be selected on the basis of, and 
qualitative interview schedules targeted towards explaining, any 
particular patterns of response. There might also be merit in 
exploring the perspectives of particular socio-demographic groups 
to get a sense of a range of different rationales.
Lastly, there is potential for an additional qualitative, deliberative 
and/or Q methodology study to run in parallel with (but separately 
from) the valuation work. This would explore more general, and in 
more depth, public perceptions of issues of interest to the funders. 
For example, using mini-publics (Escobar and Elstub, 2017) to 
investigate the views of the public in relation to contexts in which it 
might be acceptable for the value of a life year to vary and for their 
views on the process by which individual values for risk reductions 
are aggregated into a VOLY and a VPF. There are a number of 
methods that can be used, but generally deliberative approaches 
require provision of good information; time and resources for 
guided, reasoned deliberation and locating common ground, before 
coming to proposals and ideally consensus. Within the broad area 
of deliberation mixed qualitative and quantitative techniques can be 
used, including voting methods and Q methodology (Baker et al., 
2006; Baker et al., 2014b).
 3.3 Sampling
The sample size should be sufficiently large to make claims about 
representativeness of the UK general population based on 
demographic quotas for age, gender and socioeconomic classification; 
this is envisaged as no fewer than 1,000 participants. As will be 
outlined in Section 4 of this report, it will be particularly important to 
have sufficient sample size to conduct age-specific analyses.
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 3.4 Survey administration
The survey should be delivered using computer assisted technology 
to allow for personalisation of the survey design, for example based 
on respondents’ current age, projected life expectancy or health 
status. The survey could be interviewer administered or via the 
internet using an online panel and reviews by Nielsen (2010) and 
Lindhjem and Navrud (2011) comparing internet with other survey 
modes do not observe substantially different welfare estimates.
As outlined in RQII, there are trade-offs in both modes of delivery. 
Interviewer administered surveys allow respondents to ask 
questions while completing the survey to enhance comprehension 
of the task. However, there is the potential for interviewer effects 
and respondents may give what they consider to be the ‘correct’ 
answer rather than a true preference. It is also resource intensive 
and therefore sample size is likely to be reduced. Online surveys via 
internet panels give the opportunity to increase the sample size and 
to collect data faster. Surveys should be designed to be 
understandable without the aid of an interviewer, but the risk 
associated with online surveys is that respondents will ‘click 
through’ if they consider the survey to be difficult (or time 
consuming). Internet based surveys are only available to those who 
are online, and although internet penetration has significantly 
increased in the UK, there are some demographic groups (for 
example older women) who engage less online.
The survey administration mode should be justified with reference to 
the acceptability to respondents and confidence in the mode to 
convey the concepts correctly. Both interviewer-delivered and online 
modes of administration should be tested in a pilot study following 
the development of the computer assisted programme to test for 
comprehension of the exercise. A priori, given the importance of the 
proposed study and the need to have as much confidence in the 
resulting values as possible, a potential solution would be to have 
an interviewer delivered survey for the VOLY valuation data and 
on-line versions utilised to explore further, related research 
questions noted elsewhere in this report.
 3.5 Data Handling and Analysis
An appropriate data handling and analytical strategy should be 
developed that would allow for the estimation of a value function at 
the individual and aggregate level and produce a generic VOLY. The 
analytical strategy should follow practice applied in the previous 
VPF studies and remove non-traders and protest responses. 
Additionally, to ensure good practice, approaches to data cleaning 
and trimming should be considered and specified ex ante as part of 
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the design phase in advance of the data analysis. In addition, 
econometric techniques to deal with skewed data sets (common in 
all areas of non-market valuation) can also be deployed, although 
this should not substitute for collecting ‘good’ data in the first place.
Section 4 now follows in which we consider some broader cross-
cutting issues.
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4 Cross-cutting issues arising 
from the literature reviews
 4.1 Introduction
This section sets out the cross-cutting recommendations and key issues 
that apply when estimating and implementing the VOLY. Some issues 
relate to features to be accounted for if new primary research was 
undertaken, as recommended in Section 2 of this report. Other features 
relate to the application of the VOLY in policymaking and apply even if no 
new research is conducted. This report does not promise a ‘final word’ 
on the issues raised in this section, since many are a matter of 
judgement for policymakers (which could usefully be informed by new 
qualitative research). It does, however, provide our opinion on the most 
appropriate way to proceed where such an opinion can be supported by 
theoretical or empirical evidence underpinning this report.
 4.2 What would a new study aim to achieve?
Any new primary research should generate up-to-date, robust, 
reliable conclusions about the monetary VOLY according to the 
preferences of a representative sample of the UK population. The 
literature reviews and this synthesis report have highlighted the 
justification for such a study, a new conceptual framework to 
underpin it, and possible empirical approaches. However, beyond 
providing empirical estimates of the value function (Figure 1), a new 
study could provide additional benefits as follows:
	 Methodological research that investigates the robustness of new 
and existing empirical findings; explores the influence of behavioural 
biases and heuristics that may influence responses to preference 
elicitation tasks; and/or, provides the foundations for elicitation 
techniques that could be employed in future (e.g. exploring the 
potential for direct valuation of changes in survival curves).
	 Investigations into the effect of contextual features highlighted in 
RQIII and RQIV. We recommend focusing on the features that are 
theoretically relevant for the VOLY (i.e. age, discounting) or that 
have been demonstrated to matter empirically. Although a full 
empirical account of context effects would be beyond the scope 
of any single study, it may be fruitful to empirically investigate the 
most important features. Contextual features defined in terms of 
respondents’ personal characteristics (gender, location etc.) 
would be investigated as standard in an empirical study.
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	 Using a relativities approach (see RQII), alternative types of 
VOLY25 could be estimated. For example, to capture the VOLY 
generated by ongoing risk reductions, the method generated by 
Nielsen et al. (2010) could be implemented.
	 As outlined in the previous section, additional qualitative research 
could provide a measure of public understanding and 
acceptance for the implications of the quantitative findings. 
Taking this qualitative approach as a complement to the 
quantitative main study would also allow public input into some 
of the issues raised throughout this study that cannot be 
quantitatively decided, for example how they would prefer to 
resolve the incompatibility between an age-independent VOLY 
and an age-independent VPF.
 4.3 The incompatibility between a constant VPF, a 
constant VOLY and a constant WTP-QALY
Both the prevention of an immediate fatality and life expectancy 
gains could be generated by small individual one-period reductions 
in mortality risk for the affected group. For policy purposes, the 
WTP-based values are aggregated into a VPF and VOLY, 
respectively and the VOLY is given by the VPF for the affected group 
divided by mean remaining (discounted) life expectancy for the 
affected group (see also discussion in RQV). The two measure are 
thus intimately related and both are consistent with expected utility 
theory. Although some evidence exists to support an inverted 
u-shaped relationship between age and the VPF (whereby the VPF 
is lower for older and younger age groups) a constant, age-
independent VPF is applied in policy. The formal relationship above 
means that a VOLY, by definition, will be age-dependent if the VPF 
is constant. However, the application of an age-independent VPF is 
based on equity principles. If applied to the VOLY as well, then a 
conceptual incompatibility (from an efficiency point of view) between 
an age-independent VPF and an age-independent VOLY (or WTP-
QALY) cannot be avoided but can be justified on equity grounds.
To illustrate the implications of imposing an age independent VOLY 
and age-independent VPF, we set out some example projects. 
Suppose that the Government has funds to spend on one (but not 
all) of three alternative projects, A, B and C. Project A benefits 1000 
individuals of an older age with 10 years of discounted remaining life 
expectancy. Project B benefits 1000 individuals of a younger age 
with 40 years of discounted remaining life expectancy.
25 The type of risk reduction e.g. one-period or ongoing could be considered a contextual feature in the 
broader sense. While we base the proposed framework around a one-period risk reduction, to estimate 
other VOLY types would require additional questions in an empirical survey.
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Suppose projects A and B each offer a reduction of 1/1000 in the 
current period hazard rate, meaning that each prevents one 
statistical fatality. For project A, which helps the older individuals, 
this is a gain of statistical life years. For policy B, which helps the 
younger individuals, this is an improvement of statistical life years.
Project C benefits the group of 1000 older individuals, reducing their 
risk of death by 4/1000, generating a gain in life expectancy of 
statistical life years, or preventing four statistical fatalities.
Age-independent values
Suppose that the VPF is set at £1.8 million and that population average, 
appropriately discounted, remaining life expectancy is 30 years. Based 
on the argument set out in the Technical Appendix it then follows that 
the VOLY would be set equal to £1,800,000/30 = £60,000.
If we apply the age-independent VPF to policies A and B, each 
would be valued at £1.8 million and the policymakers would be 
indifferent between them. If instead we apply the age-independent 
VOLY to the policies, Policy A would be valued at £600,000 and 
Policy B would be valued at £2,400,000, with Policy B clearly 
preferred. For project C, applying a constant VOLY would mean it 
was valued at £240,000 (the same as project B) but if a constant 
VPF is applied it would be valued at £7,200,000.
Table 1  Appraising projects using age-independent VPF and VOLY
Project Discounted 
remaining 
LE of 
affected 
group 
(years)
Reduction 
in hazard 
rate 
Statistical 
fatalities 
prevented
Statistical 
life years (or 
QALYs) 
gained
Value 
assuming 
constant 
VPF = 
£1.8m
Value 
assuming 
constant 
VOLY = 
£60k
A 10 0.001 1 0.01 SLY £1.8m £600k
B 40 0.001 1 0.04 SLY £1.8m £2.4m
C 10 0.004 4 0.04 SLY £7.2m £2.4m
Using the constant VPF the preference ordering of projects would 
be C>A=B. Using the constant VOLY it would be B=C>A. This 
illustrates the inconsistency in implications. The projects are 
outlined in Table 1.
Consider an additional Project D offering a gain in QALYs of 0.02 to 
each group. Valuing this at the constant VOLY rate of £60,000, the 
value of this policy would be 0.02∙1000∙£60,000 = £1,200,000 for 
each group. Clearly, the group of older individuals would prefer 
Policy D over Policy A (since it delivers 0.02 QALYs instead of 0.01 
statistical life years). But if the constant VOLY is used to value 
project D and the constant VPF is used to value project A, then A 
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would be prioritised over D, contrary to the preferences of the 
affected group. This demonstrates that not only are the policy 
implications internally inconsistent but they have the potential to 
misallocate resources.
Age-dependent values
Finally, consider a case where the VPF and VOLY are allowed to vary 
with age. Suppose the older group report a VPF of £1.2 million with a 
VOLY of £120,000. Suppose the younger group report a VPF of £2 
million with a VOLY of £50,000. The recalculated values are presented 
in Table 2. Note the consistency within and between projects.
Table 2: Appraising projects using age-dependent VPF and VOLY
Project Discounted 
remaining 
LE of 
affected 
group 
(years)
Reduction 
in hazard 
rate 
Statistical 
fatalities 
prevented
Statistical 
life years (or 
QALYs) 
gained
Value 
assuming 
age 
dependent 
VPF
Value 
assuming 
age 
dependent 
VOLY
A 10 0.001 1 0.01 SLY £1.2m £1.2m
B 40 0.001 1 0.04 SLY £2m £2m
C 10 0.004 4 0.04 SLY £4.8m £4.8m
The additional project D would be valued at £2,400,000 for the older 
group and £1,000,000 for the younger. For the older group it would 
(correctly) be prioritised over project A and for the younger group it 
would (correctly) be passed over in favour of Policy B, regardless of 
whether the VPF or VOLY was used to value the policies.
Clearly, therefore, the use of an age-independent VPF and an age-
independent VOLY (or WTP-QALY) is likely to lead to suboptimal 
allocation of public sector funding and if this potential problem is to 
be avoided it will be necessary to allow the VOLY and/or the VPF to 
vary with age. For example, if it is decided that the VPF must be 
held constant, then the VOLY will need to be increased at an 
appropriate rate with age, whereas a constant VOLY would require 
that the VPF should be a decreasing function of age.
Our conceptual framework allows each of the VPF, VOLY and WTP-
QALY to be estimated in the special case of changes in life 
expectancy generated by one-period changes in the risk of dying (in 
the standard gamble). It does not, however, resolve the conceptual 
incompatibility for policy of an age-independent VPF and an age-
independent VOLY or WTP-QALY referred to here.
There are policy applications where the VPF, the VOLY, or the WTP-
QALY are currently deemed most appropriate. For example, the 
WTP-QALY can account for the relative value of changes in quality 
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and duration of life, the VPF is appropriate for valuing one-period 
marginal fatality risk reductions, and the VOLY handles ongoing 
changes in risks of fatality that generate changes in life expectancy.
If a constant VPF and a constant VOLY are used despite their 
fundamental incompatibility, this would imply an over-valuation of 
older members of the population compared to younger ones when 
the constant VPF is employed, and would imply over-valuation of 
younger members of the population relative to older ones when the 
constant VOLY is employed. To ascertain the magnitudes of these 
distortions, it will be necessary to estimate age-dependent values 
as benchmark against which the results of applying age-
independent values can be compared. This necessitates a large 
enough sample of respondents to elicit age-specific estimates of 
the VOLY, VPF and WTP-QALY.
To further explore the effects of age on the VOLY, it would be 
interesting to ask respondents to value risk reductions with different 
lead times, disentangling the effects of age at the time of the survey 
and age at the time of the risk reduction. Furthermore, attitudes to 
age and age-consistency in values could be explored in qualitative 
research. We consider these to be useful possible extensions of the 
current proposal, although not necessary for the operationalisation 
of the framework.
 4.4 Discounting for delay
RQIV outlined the different roles of discounting in the VOLY 
framework on two levels: the personal discount rate governing 
individuals’ valuations; and the social discount rate applied in policy 
when valuing future benefits.
Regarding personal discount rates, if individuals discount the utility 
associated with living through the future years and decades that 
make up their life expectancy, discounting will be inherent in the 
VPF and the VOLY. Earlier in this report, and in the Technical 
Appendix, we demonstrated the importance of the personal utility 
discount rate in our framework. We argue that the VOLY should be 
calculated on the basis of discounted remaining life expectancy, 
since, discounting is important in interpreting the TTO and SG 
responses, which are central to the empirical framework we 
propose. In the context of the VOLY, the personal discount rate 
brings additional considerations compared to the VPF, because the 
personal discount rate may influence preferences for gains in life 
expectancy generated in different ways, for example by one-off 
versus ongoing changes in fatality risk.
We recommend that any future empirical work should acknowledge 
the role of the personal discount rate in determining stated 
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preference responses in the VPF or VOLY context, even when the 
risk reduction is immediate and one-period in nature. Studies should 
measure and control for individual discounting, eliciting estimates of 
individuals’ time preferences as part of a large study. At the least, 
researchers should explore the robustness of their VOLY estimates 
to different discount rate assumptions.
Methods for eliciting and controlling for personal discounting are 
available. If we assume that the discount rate is portable between 
contexts, simple approximations can be made by eliciting time 
preferences through choices between smaller money amounts 
sooner versus larger ones to be received later. However, since the 
rate of discounting for money may not be the same as the rate of 
discounting for future utility, more sophisticated approaches may 
need to be adopted. Research along these lines was presented in 
McDonald et al. (2017) and further development of these approaches 
in the VOLY context is currently being underway26. Specifically, that 
project aims to develop methods for directly eliciting effective 
discount rates from choices between fatality risk reductions, and to 
ascertain the role of discounting in explaining preferences for 
different types of VOLYs.
An alternative approach would be to directly elicit discounted 
remaining life expectancy in the survey. This approach would entail 
asking respondents to engage in standard gambles between 
outcomes that would apply for the rest of one’s life. Specifically, 
they would be asked to consider a health state set to last for 1 year 
then return to normal health and imagine a treatment where, if the 
treatment is successful, it would allow the avoidance of the 
temporary health state, whilst if it is unsuccessful the temporary 
health state would persist for the rest of one’s life. The probability of 
treatment failure that would render the participant indifferent 
between the temporary illness and the gamble can be shown to 
reveal subjective discounted life expectancy. The benefit of such an 
approach is that it eliminates the need to find out specific estimates 
of discount rates for future utility. The drawback is that it does not 
provide information about the way that discounting manifests itself, 
nor on the functional form of discounting. The preferred approach 
would depend on the scope of any primary research, with more 
information about discounting preferred to less given sufficient 
scope and sample size for its meaningful analysis.
Regarding the policy application of a social discount rate to future 
gains in life expectancy, there is ongoing debate about the 
appropriate rate at which society (and hence government) ought to 
discount the future utility of generations alive today, and the utility of 
26 ESRC Grant number ES/R005893/1 ‘Discounting for delay and the value of a life year lost to air pollution’ 
2018–2020
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future generations. The literature review in RQIV outlined key 
elements of this debate and provided an overview of public opinion 
on the matter from a variety of perspectives, but ultimately the 
choice of discounting approach for application in assessment and 
appraisal of policy rests with the policymakers.
An important pitfall to avoid is to ‘double discount’ future utility. This 
could occur in situations where social discounting is applied to 
VOLY estimates for changes in risk within the lifetime of the current 
generation, since the VOLY estimates would already incorporate 
discounting at the individual’s personal rate. Two alternative 
solutions exist: first, to respect personal discount rates and not 
apply any social discounting; and second, to ‘re-inflate’ individual 
valuations to their undiscounted value and then apply the social 
discount rate instead. The latter approach requires estimates of the 
personal discount rate an individual level. The decision about which 
approach should be taken rests on whether consistency in 
discounting is perceived to be more or less important than 
respecting individuals’ personal discount rates. Note that this 
problem relates to discounting within the current generation: 
discounting of the utility of future generations is subject to a largely 
separate debate outlined in RQIV and applicable much more broadly 
than the current context.
 4.5 Dread and anxiety
The conceptual framework, preferred empirical approach, and the 
underpinning theoretical framework are based on the fact that gains 
in life expectancy can only be generated by perturbations in the 
survival function. The key underlying assumption is that the societal 
value of a reduction in fatality risk is a monetary estimate of the 
value of the gain in the total expected utility that would be enjoyed 
as a result of the risk reduction. However, it has been observed that 
individuals may not perceive hazard rate reduction in the same way 
as a gain in life expectancy, even though they are theoretically 
interchangeable. For instance, people may dread the prospect of 
sudden fatality (although existing evidence suggests there is no 
strong preference for reducing immediate risks (Nielsen et al. 2010; 
McDonald et al., 2016). People may value avoiding the grief that their 
loved ones would suffer in the event of their fatality, and they may 
feel that safety has a value per se (e.g. through reduced anxiety or 
fear) instead of as a route to additional lifetime utility.
Nevertheless, if the underlying expected utility model is appropriately 
set up then it will include (if necessary) a very high disutility 
associated with the prospect of immediate death to reflect the dread 
effects etc. referred to. This will then mean that the implied VOLY 
associated with a gain in life expectancy resulting from a reduction in 
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the hazard rate for the coming year will be very much larger than the 
VOLY for later year hazard rate reductions. As such, standard theory 
(see Jones-Lee et al., (2015)) could be extended to accommodate 
dread effects such as those described here.
Having said this, policies that generate gains in life expectancy do 
so by changing the probability of living to enjoy future periods. As 
such, we suggest that a conceptual framework such as the one we 
have proposed is a valuable approach to underpin policy evaluation 
of the value of fatality risk reduction. Nevertheless, care must be 
taken in the empirical estimation of the value function in Figure 1 to 
ensure that concerns like those we described do not unduly 
influence the values elicited. It may be appropriate to establish 
weights that could be used to amend the VOLY in circumstances 
where the safety improvements bring salient additional benefits, if 
empirical research supported their inclusion.
 4.6 Behavioural biases and heuristics
Any empirical estimation of values for changes in survival 
probabilities, whether via the chained approach or not, must 
address the possibility that preferences do not conform to the 
standard Expected Utility Theory model. In RQIV we dealt with a 
range of behavioural biases that might impact stated preference 
values. These included probability weighting, whereby individuals 
over-weight low risks and underweight high ones (relevant especially 
in Standard Gamble elicitation), loss aversion (relevant especially 
when considering Willingness to Accept for losses in life 
expectancy), preference imprecision (relevant when chaining 
responses, if the preference imprecision leads to systematically 
higher or lower responses) and non-standard discounting, such as 
hyperbolic discounting. More fundamentally, if preferences are not 
well defined over the outcomes being valued, then responses may 
not be meaningful. Further to these, we discussed a range of well-
documented survey response biases such as anchoring on previous 
cues or responses, or selecting midpoints of lists of options.
It is impossible to design empirical preference estimation 
techniques that wholly avoid such behavioural biases and 
heuristics. However, many issues can be minimised through careful 
survey design, piloting, comprehension questions and debrief. The 
proposed empirical framework helps to avoid some of the 
problems by breaking the elicitation of value into manageable 
stages such that extremes of probability need not be included, 
and by focusing on the domain of gains in life expectancy. In the 
future, even more sophisticated methods could be developed, 
such as correcting responses for the distortions introduced by, 
for example, e.g. probability weighting or loss aversion, by 
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measuring the relevant preference parameters and weighting the 
responses accordingly.
Contextual features of elicitation scenarios such as the type of injury 
or fatality risk, may also influence responses to elicitation tasks, and 
as such any future research should recognise and, ideally, control 
for the influence of the specific contextual features of the elicitation 
scenario so that the estimated VOLY would be as free from 
contextual effects as possible. Alternatively, a generic VOLY 
could be proposed since this would maximise transferability 
across policy domains.
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5 Conclusions
	 The values currently recommended in the Green Book for 
monetarising life and health impacts - the VPF, the value of a SLY 
(or VOLY) and QALY - are based on a very small sample-survey 
of the UK public carried out in the 1990s.
	 In addition, these three measures are applied in ways that reflect 
difference in foci and traditions across UK government 
Departments, which allows for flexibility in approach. However, 
there is a danger that inconsistencies in how life and health is 
valued across different Departments may arise.
	 Consistency across policy is therefore highly desirable but this 
would require a new approach, one in which the three values could 
be brought together under a unifying conceptual framework and, if 
possible, empirically derived from a common source, reflecting the 
same underlying preferences over health and safety.
	 A conceptual framework has been set out in this report and 
empirical methods identified that would achieve this requirement, 
providing a significant advance on past studies by and hence 
would generate a VOLY that has a clear conceptual link to the 
value of a QALY and a VPF
	 From a theoretical perspective, the one-period framework on 
which the proposed method is based is underpinned by recent 
theoretical work on discounting that establishes the conditions 
under which the values elicited from single and/or multi-period risk 
reductions can be expected to be equal. As such, there appears to 
be no imminent need for further theoretical development either 
prior to or during any new primary empirical research.
	 From an empirical perspective, a future study should be 
grounded in theory and reflect the fact that gains in life 
expectancy can only be generated by reducing fatality risks.
	 Methods exist to operationalise the framework presented. In 
principle, they can be deployed in a new primary study but this 
should be subject to some further investigations and 
improvements. This suggests an in-depth and intensive approach 
to piloting since concerns have been raised that the chaining 
process amplifies the effect of people’s imprecise preferences on 
valuations, thereby increasing the number of outliers.
	 Hence, any new study should incorporate existing methodological 
advances since 2011 – or develop new ones - to reduce the 
number of outlier observations excluded from the data. 
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Appropriate econometric techniques for the analysis of skewed 
data should be applied.
	 Any new quantitative primary study would benefit greatly from a 
parallel qualitative work. This could focus on methodological 
issues concerning the cognitive underpinning of responses to the 
component parts. It could also be used to explore broader issues 
such as peoples’ views on how their quantitative responses are 
used in by policymakers to value fatalities avoided, life 
expectancy gains and quality-adjusted life years and/or whether 
there are any contexts in which it might be acceptable for the 
value of a life year to vary.
	 Conceptually either the VPF or the VOLY (or both) must be age 
dependent in order for their implications for resource allocation to 
be consistent. Therefore, any survey should be sufficiently large 
to be broadly representative of the UK population and designed 
so that the calculation of age-dependant VOLYs can be estimated 
in order to further understand the relationship between age and 
the valuation of life expectancy gains and of the VPF. Wider 
public policy considerations may lead to a policy decision to 
apply a constant VOLY and a constant VPF.
	 It is clear that what can be generated from a new study depends 
on how it is resourced. To make any new primary study 
worthwhile, it is useful to think of what appears most crucial for 
policy and, if provided, whether its findings would be translatable 
into a robust updating of the Green Book.
	 Thus, we present some example options, organised into Tiers, in 
the Appendix whereby each Tier builds on and includes the 
previous Tier. With the exception of Tier 1, these should be 
considered as descriptive, rather than prescriptive. Tier 1 might 
be thought of as the ‘minimum’ that would be required for policy 
values reflective of the aforementioned criteria i.e. a 
methodologically rigorous, conceptually underpinned policy 
values. Tier 2 would extend this to incorporate a key issue that 
resonates with current policy interest but one that could also 
provide the foundations for more sophisticated evidence-based 
policymaking in the future. Finally, Tier 3 might be considered as 
primarily advancing academic inquiry into methodological and/or 
cross-cutting policy issues and, for all practicable purposes, may 
be better described as a suite of related studies.
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Technical appendix 
Estimating the WTP-based VOLY 
using the chained approach
By definition, an individual’s remaining life expectancy, E , is given by:
E = (1 - p1) + (1 - p1)(1 - p2) + (1 - p1)(1 - p2)(1 - p3) +... (1)
where pt is the “hazard rate” for year t, i.e. the probability of death 
during year t conditional on survival to the beginning of the year. For 
the sake of simplicity, the specification of E in equation (1) assumes 
that if death is to occur during year t, then it does so at the 
beginning of the year.
From equation (1) it follows that the magnitude of the increase in life 
expectancy resulting from a reduction in the hazard rate for any 
particular year will be proportional to the magnitude of the reduction 
in the hazard rate concerned. In addition, it is clear that under any 
reasonable assumptions concerning the determinants of the typical 
individual’s remaining lifetime expected utility, the magnitude of the 
increase in the latter resulting from a reduction in the hazard rate for 
any given year will also be proportional to the size of the hazard rate 
reduction. It therefore follows that the magnitude of the gain in 
lifetime expected utility will be proportional to the magnitude of the 
increase in life expectancy. Given diminishing marginal utility of 
wealth, it is therefore clear that while the individual’s willingness to 
pay, WTP, for a gain of ΔE in life expectancy will be an increasing 
function of the gain, it will increase at a decreasing rate i.e. the 
function WTP = f(∆E) will be increasing but strictly concave. Thus, to 
put it simply, if a gain ∆E in life expectancy produces an increase 
∆U in lifetime expected utility, then a gain of 2∆E in life expectancy 
will produce a gain of 2∆U in lifetime expected utility. But given 
diminishing marginal utility of wealth, the reduction in the individual’s 
wealth required to offset the gain of 2∆U in lifetime expected utility 
(i.e. the individual’s WTP for the gain of 2∆E in life expectancy) will 
be less than twice the reduction in wealth required to offset the gain 
of ∆U in lifetime expected utility (i.e. the individual’s WTP for the 
gain ∆E in life expectancy).
The graph of the function WTP = f(∆E) relating the individual’s WTP to 
his/her gain in life expectancy will therefore take the following form:
A scoping study on the valuation of risks to life and health Page 59 of 75
Health and Safety Executive
Figure A1  Relationship between WTP and gains in life expectancy (LE)
It should be noted that the negative WTP corresponding to negative 
gains in life expectancy in the graph reflects the individual’s required 
compensation i.e. his/her willingness to accept, WTA, for reductions 
in life expectancy. Given that the graph is constructed so as to pass 
smoothly through the origin, it is obviously based on the assumption 
that the individual’s preferences display no “reference point” effect 
reflecting loss-aversion. If, in fact, the individual’s preferences did 
display such an effect, then while the graph would still pass 
continuously through the origin, it would display a clear “kink” as it 
did so. However, given that the argument presented below in 
Section 1 will focus exclusively on WTP for genuine gains in life 
expectancy and will involve no reliance on the nature and magnitude 
of WTA for reductions in life expectancy, the possibility of loss-
aversion and the resultant kink at the origin of the graph will be 
irrelevant. In particular, the gradient of the chain-dotted tangent line 
to the graph at the origin should be treated as the individual’s 
marginal rate of substitution of wealth for a gain (rather than a loss) 
in life expectancy. However, the way in which the argument 
developed below in Section 1 might be adjusted to accommodate 
willingness to accept compensation for decreases in life expectancy 
and hence provide a basis for estimation of a VOLY that is 
applicable to losses - rather than gains - in life expectancy, will be 
discussed below in Section 4.1.
Clearly, if it were possible to obtain an empirical estimate of the 
parameters of the function WTP = f(∆E) for an individual (or a group 
of individuals) then it would be a straightforward matter to use the 
function as the basis for deriving an estimate of the VOLY for the 
individual (or the group of individuals) for both marginal and non-
marginal gains in life expectancy. Thus, for example, if we denote 
WTP
Gain in LE
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the ith individuals marginal rate of substitution of wealth for a gain in 
life expectancy (i.e. the gradient of the graph of WTP = f(∆E) at the 
origin) by mi, then summed across a large group of n individuals, 
aggregate willingness to pay for individual gains of 1/n of a year of 
life expectancy would be equal to ∑mi (1/n) = (1/n)∑mi which is simply 
the arithmetic mean of mi for the group concerned. But if each of 
the n individuals enjoys a marginal gain of 1/n of a year of life 
expectancy then aggregated across the group these gains sum to 
one year, so that aggregate willingness to pay can naturally be 
regarded as the Value of a Statistical Life Year or VOSLY. It therefore 
follows that the VOSLY for the group affected is given by the 
arithmetic mean of mi taken across the group.
If, by contrast, the gains in life expectancy enjoyed by individuals in 
the affected group were to be non-marginal - say 12 individuals 
each enjoying a one month gain in life expectancy - then it might be 
judged to be inappropriate to base the valuation on affected 
individuals’ marginal rates of substitution and to proceed instead on 
the basis of WTP for ∆E = 1/12, obtained from the estimated WTP = 
f(∆E) functions for the individuals concerned. Aggregated across the 
12 affected individuals, a one month gain in life expectancy per 
person would sum to one year, so that total willingness to pay for 
the group could naturally be treated as the VOLY for the affected 
group for the non-marginal gains in life expectancy. Clearly, total 
willingness to pay for the group would be 12 times the arithmetic 
mean of each affected individual’s WTP for the one month gain 
which would, in turn, be equal to the arithmetic mean of the ratio 
WTP/∆E with ∆E set equal to 1/12.
In order to derive the VOLY for non-marginal gains in life expectancy 
for a “representative group” of affected individuals it might therefore 
be argued that it would be appropriate to set the VOLY equal to the 
population mean of the ratio WTP/∆E for the relevant non-marginal 
gain of ∆E per person in life expectancy. But the question of 
whether or not it would be appropriate to employ different VOLYs for 
marginal and non-marginal individual gains in life expectancy would, 
of course, be a matter of judgement for the public sector decision-
making agency concerned.
Up to this point the argument has focused on gains in life 
expectancy - and the resultant gains in lifetime expected utility and 
hence willingness to pay - generated by a reduction in the hazard 
rate for a given year. However, it is entirely possible that the gain in 
lifetime expected utility (and hence willingness to pay) generated by 
a given gain in life expectancy may depend not only on the 
magnitude of the gain in life expectancy but also on the precise 
nature of the perturbation in the vector of future hazard rates that 
gives rise to the gain in life expectancy. If this is in fact the case 
then care must be taken to make the necessary adjustments to the 
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estimated WTP = f(∆E) function to take account of any significant 
difference between the hazard rate reductions generating the life 
expectancy gain being valued and the hazard rate reductions 
underpinning the estimated WTP = f(∆E) function.
	 1	 Empirical	estimation	of	the	WTP	=	f(∆E)	function
But all of this having been said, the fundamental question is then 
how, in practice, the underlying WTP = f(ΔE) function might best be 
estimated at both the individual and group level? Focusing on 
estimation at the individual level, it is clear that this would require 
the implementation of a carefully structured representative sample 
survey. In order to avoid the conceptual and cognitive problems 
involved in asking survey respondents to place a direct value on 
gains in life expectancy27, it would seem more appropriate to 
employ some variant of the so-called “chained” approach. This 
approach aims to break the valuation task down into two stages, 
each of which is designed to be more manageable for respondents 
from a conceptual point of view than direct valuation.
In particular, at the first stage of the chained approach the 
respondent is asked to specify his/her maximum WTP for a quick 
and complete cure for a non-fatal injury or illness of modest severity, 
with the symptoms and duration of the injury or illness clearly 
specified. At the second stage, the respondent is then presented 
with a Standard Gamble (SG) or Time-Trade-Off (TTO) question 
designed to determine the loss of life expectancy in normal (or full) 
health28 that the respondent would regard as being equally as bad 
as suffering the non-fatal injury or illness. While an individual’s 
response to a TTO question provides a direct indication of the loss 
of life expectancy in full health that the respondent regards as being 
equally as bad as suffering the non-fatal injury/illness, in the case of 
an SG question the loss of life expectancy can be derived directly 
from the maximum probability of treatment failure that the 
respondent would be prepared to accept in a treatment which, if 
successful, would result in an immediate and complete cure for the 
injury/illness, but if unsuccessful would result in immediate death. In 
particular, if the individual’s maximum acceptable probability of 
treatment failure is π (so that the individual would be prepared to 
accept an increase of π in his/her first year hazard rate by 
27 The most obvious potential problem involved in asking respondents to place a direct value on a gain in 
life expectancy is that many people will understandably - but nonetheless mistakenly - interpret a gain in 
life expectancy as an “add-on” to survival time at the end of life. If the gain is only relatively small, then it 
would not be surprising if, treated as a marginal extension to survival time at the end of life, it was regarded 
by the respondent as being of little, if any, significance.
28 Strictly speaking, TTO questions are framed in such a way as to indicate the loss of life expectancy in full 
or perfect health (rather than “normal” health) that the respondent would regard as being equally as bad 
as the non-fatal injury or illness. The implications of the possibility that the respondent may not be in full 
health will be examined below in Section 4.3.
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undergoing the treatment), then it follows from the definition of 
remaining life expectancy that undergoing the treatment would 
involve a loss of life expectancy of πE/(1-p1) which, with p1 small (as 
will typically be the case for anyone below the age of 80), is 
effectively equal to πE.
Now suppose that at the first stage the respondent states that his/
her maximum willingness to pay for a quick and complete cure for 
the injury/illness is £V and at the second stage he/she provides a 
response which implies that the illness/injury is equally as bad as 
losing ∆E years of life expectancy in normal health, thereby 
indicating that a quick and complete cure for the injury/illness yields 
the same gain in lifetime expected utility as a gain of ∆E years of life 
expectancy in normal health. It can then reasonably be concluded 
that since the individual’s maximum willingness to pay for a quick 
and complete cure is £V, then his/her maximum willingness to pay 
for a gain of ∆E years of life expectancy in normal health would also 
be £V29. In this way, the individual’s responses to the WTP and SG 
(or TTO) questions can be “chained together” to obtain an estimate 
of his/her WTP for a specific gain in life expectancy. By presenting 
the individual with WTP and SG (or TTO) questions for a number of 
different severities of non-fatal injury or illness it would then be 
possible to estimate the parameters of his/her WTP = f(∆E) function.
In order to obtain an empirical estimate of the parameters of an 
individual’s WTP = f(∆E) function from his/her responses to a set of 
WTP and SG(or TTO) questions it would clearly be necessary to 
specify a priori an hypothesis concerning the structural form of the 
function. Following the argument developed above, it is clear that 
the function would need to be strictly increasing, strictly concave 
and such that f(0) = 0. In addition, given that for the typical 
individual, budget constraints would place an upper-bound on the 
amount that he/she would be able (and hence willing) to pay for a 
gain in life expectancy - however large the gain - then it would seem 
appropriate to require that the function should be bounded-above.
Denoting WTP by V, one of the simplest functions satisfying the 
required properties would take the following form:
V = ∆E/(a + b∆E), a,b > 0. (2)
29 Strictly speaking, the chained approach provides a respondent’s WTP to avoid a small increase in the 
risk of immediate death and hence his/her WTP to avoid a small decrease in life expectancy. As such, 
this is therefore the respondent’s equivalent variation (EV) in wealth for the decrease in life expectancy, 
rather than his/her compensating variation (CV) for an increase in life expectancy. But by definition, an 
individual’s EV for a reduction in remaining life expectancy from E to E - x will necessarily be equal to his/
her CV for a gain in life expectancy from E - x to E. Given that x will typically be very small in relation to E 
(e.g. a matter of a few weeks or months relative to several years), it seems entirely reasonable to assume 
that the individual’s CV for a small gain in life expectancy from E - x to E will differ very little from his/her 
CV for the same small gain in life expectancy from E to E + x. On these grounds, the individual’s WTP 
response can reasonably be treated as a reliable indication of his/her CV for a gain, x, in life expectancy 
from its current level, E.
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Differentiating with respect to ∆E , it therefore follows that:
dV/d∆E = a/(a +b∆E)2 (3)
From equations (2) and (3) it is clear that ∆E = 0 => V = 0; that V is a 
strictly increasing and strictly concave function of ∆E and also that 
as ∆E  ∞ so V  1/b, i.e. V is bounded above by 1/b. The 
function therefore satisfies the basic conditions set out above.
In order to obtain an empirical estimate of the parameters of the 
function using simple regression analysis, it would seem appropriate 
to make the following simple rearrangement:
∆E/V = a + b∆E. (4)
A straightforward bivariate linear regression analysis of ∆E/V on ∆E 
would then provide the required estimates of the parameters a and 
b. Following the argument developed above, the VOLY for marginal 
individual gains in life expectancy would then be given by the 
population mean of the derivative, dV/d∆E, evaluated at ∆E = 0 
which, from equation (3), would be equal to 1/a, while the VOLY for 
non-marginal individual gains would be given by the population 
mean of V/∆E which, from equation (4), would be given by 1/(a + 
b∆E).
In fact, a version of the chained approach was employed by Donald 
Franklin in his 2015 paper “Derivation of the monetary value of a 
QALY or SLY” to obtain estimates of the population average WTP to 
avoid the QALY losses resulting from two non-fatal injuries. In 
particular, using the sample mean WTP responses reported in 
Carthy et al. (1999) for a quick and complete cure for injury W (two 
or three days in hospital; slight or moderate pain; full recovery after 
three or four months) and injury X (two weeks in hospital; some 
ongoing pain/discomfort; full recovery after 18 months) updated to 
2014 prices, i.e. £3,193 for W and £9,689 for X, and the population 
average QALY losses associated with the injuries, i.e. 0.037 for W 
and 0.2 for X, Franklin estimates the VOLY for the non-marginal 
QALY gain associated with a cure for injury Was £3193/0.037 = 
£86,297 and the VOLY for the non-marginal QALY gain associated 
with a cure for injury X as £9689/0.2 = £48,445.
As already noted, the QALY gains used in Franklin’s calculations are, 
strictly speaking, indications of the gain in life expectancy in full or 
perfect health that the average individual would regard as being 
equally as desirable as a quick and complete cure for the non-fatal 
injury concerned and it is clearly possible that this might differ 
somewhat from the gain in life expectancy in the average individual’s 
normal (and therefore possibly less than perfect) health that he/she 
would regard as being equally as desirable as a quick and complete 
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cure for the non-fatal injury30. While this possible difference is 
clearly a matter that requires careful consideration, the potential 
problem will be set aside for the time being and the implications of 
assuming that the QALY gains can be treated as gains in life 
expectancy in normal health will be explored.
Thus, if we treat Franklin’s WTP = £3,193 for ∆E = 0.037 and WTP = 
£9,689 for ∆E = 0.2 as constituting two observations from the 
“population average” WTP = f(∆E) function, then assuming that the 
function takes the form specified above in equation (2), it follows that 
a = 0.0954 x 10-4 and b = 0.5552 x 10-4. It therefore follows that the 
VOLY for marginal gains in life expectancy (i.e. 1/a) is £104,822, while 
the VOLY for non-marginal gains of one week per person (i.e. 1/(a + 
b[1/52])) is £94,271 and the VOLY for non-marginal gains of one 
month per person (i.e. 1/(a + b[1/12]) is £71,293. Using the estimated 
WTP = f(∆E) function to mirror Franklin’s calculation of the VOLY 
implied by the non-marginal gain of 0.2 years per person (i.e. 1/(a + 
b[1/0.2])) yields a figure of £48,440 which, given that Franklin’s 
estimate is £48,445, is rather reassuring! In turn, the estimated WTP 
= f(∆E) function allows the calculation of the non-marginal gain in life 
expectancy per person that would imply a VOLY equal to Franklin’s 
recommended figure for policy purposes of £60,000, which would be 
the gain, ∆E , such that 1/(a + b∆E) = 60,000. Solving for ∆E yields 
the result ∆E = 0.1284, i.e. a gain of roughly 47 days per person.
 2 Discounting and the relationship between responses to TTO 
and SG questions
However, this estimate of the parameters of the “population 
average” WTP = f(∆E) function has relied on the assumption that the 
QALY losses used by Franklin can be treated as losses of life 
expectancy in normal health and, as already noted, this may involve 
some degree of error given that the TTO questions used to estimate 
the QALY losses are framed in terms of losses of life expectancy in 
full or perfect health rather than “normal” health.
But an arguably more significant difficulty involved in relating the 
estimated WTP = f(∆E) function derived from QALY losses and the 
corresponding estimate of the function based on responses to a 
30 In fact, the typical TTO question effectively asks the respondent to specify the time in full or perfect health 
that he/she would regard as being equally desirable as spending 10 years suffering the health impairment 
being valued. If the response is T years, then spending one year with the impairment is treated as being 
equivalent to spending T/10 years in full or perfect health so that the QALY associated with the impairment 
is set equal to T/10. This, in turn, can be taken to imply that spending one year with the impairment is 
equivalent to losing 1- (T/10) years in full or perfect health. However, if the respondent is already in less 
than full or perfect health then his/her indication that T years in full or perfect health would be equally as 
desirable as spending 10 years suffering the health impairment is actually an indication that suffering the 
health impairment in addition to whatever other health limitation he/she is subject to is equivalent losing 1- 
(T/10) years in full or perfect health. Arguably therefore, the QALY loss estimated using the TTO approach 
will, If anything, somewhat overstate the loss of life expectancy in full or perfect health that is equivalent to 
suffering the health impairment concerned.
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standard gamble (SG) question arises as a result of the fact that, in 
modelling the typical individual’s response to both TTO and SG 
questions one should, strictly speaking, apply a personal discount 
rate to the stream of the individual’s future annual utilities when 
calculating his/her remaining lifetime expected utility. Thus, suppose 
that in response to a TTO question an individual indicates that 
spending T years in full health would be equally as desirable as 
spending 10 years with a particular illness or injury. Then denoting 
the utility of spending one year in full health by U and the utility of 
spending one year with the injury/illness by H, then under the TTO 
approach it is typically inferred that 10H = TU so that H/U = T/10 
and hence that the QALY associated with one year suffering the 
illness is T/10. But if the individual actually applies a non-zero 
personal discount rate to his/her stream of future annual utilities 
then, strictly speaking, the appropriate discount factor should be 
applied to both T and 10 in computing the ratio H/U. However, given 
the relatively short durations involved and personal annual discount 
rates in the region of 6% , then for other than very serious illnesses 
or injuries yielding very small values of T in response to the TTO 
question, the error involved in setting H/U = T/10 will not be large31. 
But in the case of an SG question that asks for the maximum 
increase, π , in the risk of immediate death that the respondent 
would be prepared accept in a treatment which, if successful, would 
cure the injury/illness, it would appear to be essential to take 
account of discounting of future utilities. Thus, suppose that the 
individual is asked to assume that, if untreated, the injury/illness will 
last for one year and he/she indicates that the maximum risk of 
treatment failure (resulting in immediate death) that he/she will 
accept is π. Then denoting his/her remaining discounted life 
expectancy (computed using his/her personal discount rate) by Ê 
and setting the utility of death at zero, it follows that:
H + (Ê- 1)U = (1 - π)ÊU (5)
and hence, from equation (5), that:
H/U = (1 – πÊ). (6)
31 Thus, for example, at a personal annual discount rate of 6%, ten years spent suffering an illness/injury with 
annual utility H would yield a total discounted utility of 7.3601H. If T years in full health, yielding an annual 
utility U, were to afford the same discounted utility as ten years suffering the illness/injury, then denoting 
the present value of an annuity of T years discounted at an annual rate of 6% by Td , it would necessarily 
be the case that Td U = 7.3601H and hence the response to the TTO question would be such that Td = 
7.3601 H/U. Suppose, then, that in fact H/U = 0.8. At a personal annual discount rate of 6% the response 
to the TTO question would be such that Td = 5.8881 which, at an annual discount rate of 6%, corresponds 
to a value of T of roughly 7.5. The individual’s response to the TTO question would therefore be that 7.5 
years in full health would be equivalent to spending ten years suffering the injury/illness. If the effect of 
discounting was ignored and the H/U ratio taken to be 7.5/10 = 0.75, then this would clearly involve an 
underestimate of the true ratio (i.e. 0.8) of about 6%. If, by contrast, the illness/injury was more serious with 
H/U = 0.2, then at a personal annual discount rate of 6% the response to the TTO question would be such 
that Td = 1.47 which corresponds to a value of T of about 1.6. Interpreting this as implying a H/U ratio of 
0.16 would therefore involve an underestimate of about 20%. 
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It is therefore clear that if the individual’s answer, T , to the TTO and, π , 
to the SG questions are both rational then T and π will be such that :
T/10 = (1 - πÊ). (7)
The loss of life expectancy equivalent to suffering the illness/injury 
for one year implied by the response to the SG question (i.e. πÊ) will 
be equal to the loss of life expectancy equivalent to suffering the 
illness/injury for one year implied by the response to the TTO 
question (i.e. 1 –T/10) only if the loss of life expectancy derived from 
the response to the SG question is computed on a discounted basis 
using the appropriate personal rate of time preference. The intuitive 
explanation for this that if reductions in the stream of an individual’s 
expected future annual utilities is to produce the same loss of 
lifetime expected utility as suffering the injury/illness for the coming 
year, then the reductions in the stream of expected future utilities 
must be subjected to discounting at the individual’s personal rate of 
time preference. This, in turn, clearly requires that the reductions in 
life expectancy that give rise to the reductions in expected future 
annual utilities must also be appropriately discounted.
It should also be noted that since equation (7) implies that the loss 
of life expectancy derived from the response TTO question is equal 
to πÊ, then the loss inferred from the TTO question will necessarily 
be the loss of discounted life expectancy equivalent to the injury/
illness concerned. This having been said it should be added that, 
strictly speaking, precise equality between the loss of life 
expectancy implied by the TTO response and the loss implied by 
the SG response would also require that the TTO response should 
be adjusted to take account of discounting, but as already noted, 
the error involved in failing to make this adjustment will be 
substantial only in the case of more serious illnesses or injuries.
 3 Comparison of the Franklin TTO-based VOLY estimates with 
estimates based on SG responses
In order to compare the VOLY estimates derived using Franklin’s 
version of the chained approach (which employed the TTO-based 
estimates of the QALYs associated with injuries W and X to derive 
the corresponding equivalent losses of discounted remaining life 
expectancy) with the VOLY estimates derived under the chained 
approach using the responses to the SG questions from the Carthy 
et al. (1999) study, it will be assumed a) that average remaining life 
expectancy is 40 years which, applying a discount rate of 6%, 
converts to 15 discounted life years, and b) that the appropriate 
central-tendency measures of the Carthy et al. (1999) SG responses 
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are the median probabilities32. Based on these assumptions, the 
changes, π, in the hazard rate for the coming year that are 
equivalent to injuries W and X are 0.0021 and 0.011 respectively 
which, with discounted remaining life expectancy set at 15 years, 
yields equivalent gains, ∆E, in discounted life expectancy of 0.0315 
for W and 0.165 for X, which do not differ greatly from Franklin’s 
TTO-based QALY loss figures of 0.037 for W and 0.2 for X. Using 
the Carthy et al. (1999) SG-based ∆E figures yields estimates of the 
parameters of the V = f(∆E) function specified above in equation (2) 
of a = 0.0818 x 10-4 and b = 0.5367 x 10-4, which are similar to those 
derived using Franklin’s QALY loss figures. Using these parameter 
estimates, the implied VOLY for marginal gains in discounted life 
expectancy is £122,249, while the VOLYs for non-marginal gains in 
discounted life expectancy of one week per person and one month 
per person are, respectively, £108,554 and £79,032, which are not 
grossly dissimilar to the Franklin figures of £104,822, £94,272 and 
£71,293. In the case of the VOLY for a non-marginal gain in 
discounted life expectancy of 47 days per person (which, under 
Franklin’s approach, implied his recommended VOLY of £60,000), 
the VOLY implied by the Carthy et al. (1999) SG-based parameters is 
£66,265. Of course, the clear similarity between the VOLY estimates 
derived using the Franklin TTO-based QALY losses and those 
obtained using the Carthy et al. (1999) SG results does depend on 
the use of the latter to derive the implied changes in discounted life 
expectancy. If, instead, the Carthy et al. (1999) SG results were used 
to derive the implied changes in undiscounted life expectancy then 
this would mean that all of the implied VOLY estimates derived 
above would effectively be multiplied by a factor of 15/ 40, which 
would imply that the VOLY figures for gains in discounted life 
expectancy would have to be reduced by over 60% in order to 
convert them to VOLYs for gains in undiscounted life expectancy.
All of this having been said, it should be emphasised that the SG 
questions used in the Carthy et al. (1999) study effectively required 
respondents to specify the increase in the risk of immediate death 
that would be equally as undesirable as suffering the injury 
concerned, with the duration of the health impairments resulting 
from the injury being only three or four months in the case of injury 
W and 18 months in the case of injury X. If, by contrast, the SG 
question is framed in terms of suffering the symptoms of an injury or 
illness every year for the rest of life (as in, for example, the study 
reported in Baker et al. (2010)), then it follows from expected-utility 
theory that the increase, δ, in the probability of immediate death that 
a respondent would regard as being equally as undesirable as 
32 Given that the mean SG responses in the Carthy et al. (1999) study are up to four times larger than the 
medians, this clearly reflects the impact of some upper-tail outliers, so that the medians would appear to 
be the more appropriate central tendency measures in making a comparison with the implications of the 
TTO-based results.
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suffering the symptoms of the injury or illness for the rest of his/her 
life would be such that:
ÊH = (1 – δ)ÊU (8)
where, as above, Ê denotes discounted remaining life expectancy, H 
denotes the utility of one year spent suffering the injury/illness and U 
denotes the utility of one year in full health. It therefore follows from 
equation (8) that H/U = 1 - δ, and hence 1 – (H/U) = δ, so that the loss 
of discounted life expectancy that the respondent regards as being 
equivalent to suffering one year of the injury/illness (i.e. 1 – (H/U)) is 
equal to the increase, δ , in the probability of death specified by the 
respondent in answer to the “ suffer the symptoms of the injury/illness 
every year for the rest of life” version of the SG question.
 4 Some remaining issues
In addition to the points discussed so far, there remain three 
potentially important issues that have been mentioned in passing, 
but not discussed in detail. In particular, these are a) the derivation 
of a VOLY (or set of VOLYs) that would be applicable to losses, 
rather than gains, in life expectancy; b) the extent to which it might 
be necessary to adjust the VOLY estimated on the basis of gains in 
life expectancy generated by reductions in the hazard rate for the 
coming year in order to derive a VOLY that is applicable to gains in 
life expectancy generated by other types of perturbation in the 
vector of future hazard rates, such as a constant ongoing or 
proportional reduction in all of an individual’s future hazard rates; 
and c) the possibility that a VOLY estimated using WTP to avoid the 
TTO-based QALY loss resulting from a given injury/ illness might 
differ from the VOLY estimated using WTP to avoid the loss of life 
expectancy equivalent to the injury/illness derived from the 
response to an SG question, given that TTO questions are typically 
framed in terms of “full health”, whereas SG questions are framed in 
terms of the possibility of a return to “normal health”.
 4.1 Estimating a VOLY for losses of life expectancy
In order to derive a VOLY that is applicable to a loss, rather than 
gain, of life expectancy, there are two obvious possible procedures. 
The first would be simply to rely on the WTP = f(∆E) function 
estimated from observed willingness to pay responses for gains in 
life expectancy and use the estimated function to derive the 
negative WTP (i.e. willingness to accept compensation (WTA)) for 
negative values of ∆E (i.e. losses of remaining life expectancy). This 
approach would obviously rely on the implicit assumption that the 
underlying WTP = f(∆E) function passes smoothly through the origin 
and that there is therefore no “reference point” effect reflecting loss-
aversion. The alternative approach would be to estimate a separate 
WTP = f(∆E) function relating negative values of WTP (i.e. WTA) to 
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negative values of ∆E (i.e. losses of remaining life expectancy) on 
the basis of observations concerning the sums that individuals 
indicate they would be prepared to accept as compensation for 
suffering specified injuries or illnesses.
If we actually apply the first approach and use the estimated 
parameters of f(∆E) derived above from the Carthy et al. (1999) mean 
WTP responses for injuries W and X, together with Franklin’s TTO-
based QALY losses, then the implied mean WTA for injury W is 
£4,940 which is less than 25% of the mean WTA response for injury 
W reported in Carthy et al. (1999) updated to 2014 prices 
(i.e.£22,022). In addition, with the function f(∆E) taking the form 
specified above in equation (2) it follows that as ∆E  - a/b, then 
WTP  - ∞ , so that no sum, however large, would compensate for 
a loss of remaining life expectancy equal to or in excess of a/b. The 
“maximum acceptable” loss of life expectancy can therefore be 
treated as a/b which, based on the parameters of f(∆E) estimated 
above, is equal to (0.0954 x 10–4) / (0.5552 x 10–4) = 0.1718. Thus, 
according to this result, no sum - however large - should be 
acceptable as compensation for a loss of life expectancy equal to or 
in excess of 0.1718 years which, given that injury X involves a QALY 
loss of 0.2, sits somewhat uncomfortably with Carthy et al.’s (1999) 
finding that the mean WTA for injury X (updated to 2014 prices) was 
only £62,177. Clearly, therefore, if we take the Carthy et al. (1999) 
mean WTA results as a true reflection of the typical individual’s 
willingness to accept compensation for losses of remaining life 
expectancy, then it would appear to be necessary to estimate a 
separate f(∆E) function (possibly with a specification that differs 
from that given above in equation (2)) in order to derive VOLY 
estimates for losses, rather than gains, in remaining life expectancy.
 4.2 Different types of perturbation in the vector of future hazard rates.
Turning to the question of how the VOLY might be affected by the 
nature of the perturbation in the vector of future hazard rates that 
generates a given gain in remaining life expectancy, it is clear that if 
a given gain in an individual’s undiscounted life expectancy is 
generated by a reduction in one (or some) of his/her later hazard 
rates, then the gain in expected utility resulting from the hazard rate 
reduction will be subject to discounting at the individual’s personal 
rate of time preference. The resultant gain in discounted expected 
utility will therefore be less than the gain in discounted expected 
utility resulting from the same gain in undiscounted life expectancy 
generated by a reduction in an earlier hazard rate. The individual’s 
willingness to pay for the gain in undiscounted life expectancy 
generated by the later hazard rate reduction will therefore be less 
than his/her willingness to pay for the same gain in undiscounted life 
expectancy generated by a reduction in an earlier hazard rate. The 
magnitude of the VOLY applicable to gains in undiscounted life 
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expectancy will therefore clearly depend on the precise nature of 
the perturbation in the vector of future hazard rates that generates 
the gains concerned. However, as shown in Jones-Lee et al. (2015), 
if gains in life expectancy are computed on a discounted basis using 
the personal rate of time preference, then under reasonable 
assumptions concerning the pattern of anticipated future annual 
utilities, the VOLY will be completely independent of the nature of 
the hazard rate reductions that give rise to the gain in discounted 
life expectancy. This, together with the argument developed above 
concerning the appropriate interpretation of TTO-based QALY losses 
and SG results, clearly provides a rather persuasive case in favour of 
defining the VOLY on the basis of gains in discounted life expectancy.
 4.3 The “full health” vs “normal health” distinction
This then leaves the question of how to deal with the “full health” vs 
“normal health” distinction. It is clearly necessary to take account of 
this distinction if there is to be complete compatibility between 
VOLY estimates derived from TTO-based QALY losses and those 
obtained from the results of an SG-based study. In fact, the most 
straightforward indication of the implications of the distinction would 
appear to be provided by the results of a study reported in Mason 
et al. (2009). In particular, since a gain, ∆E , in life expectancy in full 
health would naturally be regarded by the typical individual as being 
more desirable than the same gain in life expectancy in normal 
health (which, for most people, will inevitably involve at least some 
health impairments at some stages in life), it can reasonably be 
expected that the VOLY estimated on the basis of WTP for a gain, 
∆E , in life expectancy in normal health will be less than the figure 
that would emerge if the gain, ∆E , was adjusted to produce the 
equally desirable smaller gain in life expectancy in full health. By 
applying these downward adjustments to the implied gains in life 
expectancy using the UK population norms for EQ-5D QALY 
weights reported in Kind et al. (1999), Mason et al. (2009) find that 
the VOLY based on WTP for a gain in life expectancy in normal 
health is roughly 20% smaller than the figure which emerges 
following the downward adjustment to produce the equivalent gain 
in life expectancy in full health.
Thus, given the “full health” vs “normal health” distinction, if VOLY 
estimates are derived under the chained approach using SG-based 
gains in life expectancy (rather than TTO-based QALY gains), and 
these estimates are to be used to value QALY gains, then the VOLY 
estimates will not only need to be defined in terms of appropriately 
discounted life expectancy as argued above in Section 2, but will 
also require upward adjustment by about 20% in order to 
accommodate the “full health” vs ”normal health” distinction. By 
contrast, it is clear that if instead the chained approach is applied in 
the manner employed by Franklin (2015) using TTO-based QALY 
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gains, then the resultant VOLY estimates will be directly applicable 
to the valuation of QALY gains.
 5 Practical implementation of the chained approach
Finally, it has to be admitted that the empirical estimation of the 
willingness to pay for gains in life expectancy function, WTP = f(∆E) 
, using the chained approach set out above is purely illustrative and 
has, of necessity, been based on just two different severities of non-
fatal injury. The estimation has also used sample mean values for 
WTP, population mean figures for avoided QALY losses and sample 
medians for SG responses, rather than individual responses. Ideally, 
a full-scale study using the chained approach would be based on a 
larger number of severities of non-fatal injury or illness (for practical 
reasons, perhaps three or four). In addition, given the potential 
problems associated with averaging and aggregation inherent in the 
chained approach - see, for example, Baker et al. (2010), Chapter 6 
– it would seem appropriate to estimate the underlying WTP = f(∆E) 
function at both an aggregate and individual level and, when doing 
so at the aggregate level, to employ sample medians as well as 
means. In this way it should be possible to identify and allow for the 
potentially distortional effects of dubious “outlier” responses.
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Appendix 
Alternative options for new primary 
research study
All tiers
Underpinned by some common features:
	 A generic’ VOLY’. 
	 Intensive piloting.
	 An accommodation of the central role of time discounting by 
measuring respondents’ personal rate of time preference. 
	 Split-sampling. The nature of this cannot be identified a priori since 
it depends on the issue being investigated. For example, some 
methodological issues can be investigated using a within-sample 
approach, while others cannot. Triangulation or additional significant 
empirical investigations will almost certainly require a between-
sample design.  This means it is impossible to be indicative about 
sample sizes for Tiers 2 and 3 since this will be dependent on the 
issue or issues investigated. But broadly speaking, a new issue or a 
between sample design would require doubling the sample size.
Tier 1
	 A quantitative survey to estimate VPF, VOLY and WTP-QALY. It 
should be sufficiently large to further understand the relationship 
between the different measures. For the purposes of illustration 
assuming a sample size in the range 1,000-2,000, at the lower 
end a VOLY could be estimated controlling for the effect of age; 
at the higher end robust statistical analysis would enable the 
calculation of age-dependent VOLYs to establish if and how the 
value of the three measures changes with age.
	 A qualitative study focussed on the cognitive underpinning of 
responses to the component parts to improve the robustness of 
the quantitative data.
Depending on how many health states were to be valued on the 
valuation curve; piloting may establish the need for a split sample 
approach. If so, this would increase the sample size needed to 
estimate a VOLY controlling for age.
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Tier 2
As Tier 1 but extended to investigate a key issue such as
	 Theoretically, equivalence in VOLY values has been established if 
life expectancy is discounted but empirical differences may arise 
for other reasons. Thus, a relative risk approach could be 
deployed to explore empirically if and/or how the values change 
when elicited under a multi-period framework.
	 explore what people think about how such data is used to value 
mortality risks and whether there are some circumstances in 
which it might be acceptable for the value of a life year to vary.
Tier 3
As Tier 2 (assuming one key issue investigated)
	 the other key issue
And one or more of
	 the impact of a behavioural bias or anomaly on responses
	 a full triangulation exercise using a method that is demonstrably 
equivalent to or superior to the proposed method
	 A systematic examination of different contextual effects
With respect to the last three possibilities, these are all analogous to 
how the VPF has been investigated over a number of years as 
opposed to being incorporated into an initial study primarily 
focussed on establishing and developing the value elicitation 
mechanism per se. Whilst it may be possible to explore them all 
simultaneously it may not even be desirable. Whilst some lessons 
are transferable from the VPF and WTP-QALY literature there are 
likely to be new issues relating to the VOLY that arise in the context 
of the new primary study that would be more useful to investigate in 
the future.
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Annexes
	 Annexe I: RQI: What are the relevant published estimates of the 
Value of a Life Year, and what are their strengths and 
weaknesses?
	 Annexe II: RQII: What are the main methodological issues in 
deriving a Value of a Life Year and what approaches exist in 
literature for addressing these?
	 Annexe III: RQIII: Can a Value of a Life Year be derived which is 
compatible with a Quality-Adjusted Life Year framework?
	 Annexe IV: RQIV Is it possible to derive a context-free Value of a 
Life Year for application across different policy contexts?
	 Annexe V: RQV: What is the relationship between the Value of a 
Life Year and the Value of a Prevented Fatality?
